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Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and
pulmonary embolism (PE), occurs in ;1 to 2 individuals per 1000 each year, corresponding to
;300000 to 600000 events in the United States annually.
Objective: These evidence-based guidelines from the American Society of Hematology (ASH) intend
to support patients, clinicians, and others in decisions about treatment of VTE.
Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from
conflicts of interest. The McMaster University GRADE Centre supported the guideline development
process, including updating or performing systematic evidence reviews. The panel prioritized clinical
questions and outcomes according to their importance for clinicians and adult patients. The Grading of
Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess
evidence and make recommendations, which were subject to public comment.
Results: The panel agreed on 28 recommendations for the initial management of VTE, primary
treatment, secondary prevention, and treatment of recurrent VTE events.
Conclusions: Strong recommendations include the use of thrombolytic therapy for patients with PE and
hemodynamic compromise, use of an international normalized ratio (INR) range of 2.0 to 3.0 over a lower
INR range for patients with VTE who use a vitamin K antagonist (VKA) for secondary prevention, and use of
indefinite anticoagulation for patients with recurrent unprovoked VTE. Conditional recommendations include
the preference for home treatment over hospital-based treatment for uncomplicated DVT and PE at low risk
for complications and a preference for direct oral anticoagulants over VKA for primary treatment of VTE.
Summary of recommendations
Initial management
Recommendation 1. For patients with uncomplicated deep vein thrombosis (DVT), the American
Society of Hematology (ASH) guideline panel suggests offering home treatment over hospital treatment
(conditional recommendation based on low certainty in the evidence of effects ÅÅ○○).
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Remarks: This recommendation does not apply to patients who
have other conditions that would require hospitalization, have
limited or no support at home, and cannot afford medications or
have a history of poor compliance. Patients with limb-threatening
DVT or a high risk for bleeding and those requiring IV analgesics
may benefit from initial treatment in the hospital.
Recommendation 2. For patients with pulmonary embolism
(PE) with a low risk for complications, the ASH guideline panel
suggests offering home treatment over hospital treatment (condi-
tional recommendation based on very low certainty in the evidence
of effects Å○○○).
Remarks: Clinical prediction scores have, at best, a moderate
ability to predict patient outcomes and, therefore, do not replace
clinical judgment. However, they may help to select patients at low
risk for complications. The Pulmonary Embolism Severity Index
(PESI)1 and simplified PESI2 have been most widely validated. This
recommendation does not apply to patients who have other
conditions that would require hospitalization, have limited or no
support at home, and cannot afford medications or have a history of
poor adherence. Patients with submassive (ie, intermediate-high
risk) or massive PE or at high risk for bleeding and those requiring
IV analgesics may benefit from initial treatment in the hospital.
Recommendation 3. For patients with DVT and/or PE, the ASH
guideline panel suggests using direct oral anticoagulants (DOACs)
over vitamin K antagonists (VKAs) (conditional recommendation
based on moderate certainty in the evidence of effects ÅÅÅ○).
Remarks: This recommendation may not apply to certain sub-
groups of patients, such as those with renal insufficiency (creatinine
clearance ,30 mL/min), moderate to severe liver disease, or
antiphospholipid syndrome.
Recommendation 4. For patients with DVT and/or PE, the ASH
guideline panel does not suggest 1 DOAC over another (conditional
recommendation based on very low certainty in the evidence of
comparative effects Å○○○).
Remarks: Factors, such as a requirement for lead-in parenteral
anticoagulation, once- vs twice-daily dosing, and out-of-pocket cost
may drive the selection of specific DOACs. Other factors, such as
renal function, concomitant medications (eg, need for a concomitant
drug metabolized through the CYP3A4 enzyme or P-glycoprotein),
and the presence of cancer, may also impact DOAC choice.
Recommendation 5. In most patients with proximal DVT, the
ASH guideline panel suggests anticoagulation therapy alone over
thrombolytic therapy in addition to anticoagulation (conditional
recommendation based on low certainty in the evidence of effects
ÅÅ○○).
Remarks: Thrombolysis is reasonable to consider for patients with
limb-threatening DVT (phlegmasia cerulea dolens) and for selected
younger patients at low risk for bleeding with symptomatic DVT
involving the iliac and common femoral veins (higher risk for more
severe postthrombotic syndrome [PTS]3). Patients in these
categories who value rapid resolution of symptoms, are averse to
the possibility of PTS, and accept the added risk of major bleeding
may prefer thrombolysis. The use of thrombolysis should be rare for
patients with DVT limited to veins below the common femoral vein.
Recommendation 6. For patients with PE and hemody-
namic compromise, the ASH guideline panel recommends using
thrombolytic therapy followed by anticoagulation over anticoagula-
tion alone (strong recommendation despite low certainty in the
evidence of effects ÅÅ○○).
Remarks: Strong recommendations based on low certainty in the
evidence are exceptional. In this case, the high mortality of patients
with PE and hemodynamic compromise, as well as the potential
lifesaving effect of thrombolytics, warranted a strong recommen-
dation. This exception is in accordance with the exceptional
circumstances that allow strong recommendations based on low-
certainty evidence in the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) ASH rules.
Recommendation 7. For patients with PE with echocardiogra-
phy and/or biomarkers compatible with right ventricular dysfunction
but without hemodynamic compromise (submassive PE), the ASH
guideline panel suggests anticoagulation alone over the routine use
of thrombolysis in addition to anticoagulation (conditional recom-
mendation based on low certainty in the evidence of effects
ÅÅ○○).
Remarks: Thrombolysis is reasonable to consider for submassive
PE and low risk for bleeding in selected younger patients or for
patients at high risk for decompensation due to concomitant
cardiopulmonary disease. Patients with submassive PE should be
monitored closely for the development of hemodynamic compromise.
Recommendation 8. For patients with extensive DVT in whom
thrombolysis is considered appropriate, the ASH guideline panel
suggests using catheter-directed thrombolysis over systemic
thrombolysis (conditional recommendation based on very low certainty
in the evidence of effects Å○○○).
Remarks: Given the very-low-certainty evidence (uncertainty
regarding the benefits and harms of catheter-directed thrombolysis
compared with systemic thrombolysis), the panel followed the
GRADE ASH rules and issued a conditional recommendation.
However, 4 panel members believed the recommendation should
have been graded as strong based on the lack of evidence showing
meaningful clinical benefits outweighing the known bleeding risks
associated with systemic thrombolysis.
Recommendation 9. For patients with PE in whom thrombol-
ysis is considered appropriate, the ASH guideline panel suggests
using systemic thrombolysis over catheter-directed thrombolysis
(conditional recommendation based on very low certainty in the
evidence of effects Å○○○).
Remarks: This recommendation reflects uncertainty about catheter-
directed thrombolysis for PE rooted in the paucity of randomized trial
data and variability in procedural experience across centers. In
centers with the appropriate infrastructure, clinical staff, and
procedural experience, catheter-directed thrombolysis may be an
alternative to systemic thrombolysis, especially for patients with an
intermediate to high risk for bleeding, because the total dose and
duration of administration of thrombolytic agents are lower when
delivered by catheter.
Recommendations 10 and 11. For patients with proximal DVT
and significant preexisting cardiopulmonary disease, as well as for
patients with PE and hemodynamic compromise, the ASH guideline
panel suggests anticoagulation alone rather than anticoagulation plus
insertion of an inferior vena cava (IVC) filter (conditional recommen-
dations based on low certainty in the evidence of effects ÅÅ○○).
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Remarks: These recommendations apply to patients who are
eligible to receive anticoagulation. For patients with a contraindication
to anticoagulation, insertion of a retrievable IVC filter may be indicated
with retrieval as soon as the patient is able to receive anticoagulation.
Primary treatment
Primary treatment refers to the minimal length of time a patient must
be on therapeutic anticoagulation to treat the initial venous
thromboembolism (VTE) before consideration is given to discontin-
uing anticoagulation or switching to a long-term anticoagulation
regimen aimed at preventing VTE recurrence (secondary pre-
vention) (Figure 1). Recommendations 12 through 14 refer to the
length of time for primary treatment of the initial VTE in 3 patient
populations.
Recommendations 12, 13, and 14. For primary treatment of
patients with DVT and/or PE, whether provoked by a transient risk
factor (recommendation 12) or by a chronic risk factor (recom-
mendation 13) or unprovoked (recommendation 14), the ASH
guideline panel suggests using a shorter course of anticoagulation
for primary treatment (3-6 months) over a longer course of
anticoagulation for primary treatment (6-12 months) (conditional
recommendations based on moderate certainty in the evidence of
effects ÅÅÅ○).
Remarks: These recommendations are intended to address the
duration of primary anticoagulant treatment for all patients with DVT
and/or PE, defined as the minimal length of time for treatment of the
initial VTE (Figure 1). Most patients with DVT and/or PE provoked
by temporary risk factors will discontinue anticoagulant therapy after
completion of the primary treatment. In contrast, many patients with
DVT and/or PE provoked by chronic risk factors, as well as patients
with unprovoked DVT and/or PE, may continue anticoagulant
therapy indefinitely for secondary prevention after completion of the
primary treatment (Figure 1). However, if patients and clinicians
decide to stop anticoagulation, the ASH guideline panel suggests
against using a longer course of primary anticoagulant therapy
(6-12 months). For selected patients with a chronic risk factor for
which some improvement is expected over time (eg, improved
mobility with rehabilitation), a longer course of anticoagulation for
the primary treatment phase (eg, 6-12 months) could be justified.
Secondary prevention
Following completion of primary treatment for the initial VTE,
providers must decide whether to discontinue anticoagulant
therapy or continue with long-term anticoagulation with the intent
to prevent VTE recurrence, referred to as secondary prevention.
Recommendations 15 through 19 address which patients should
be considered for indefinite secondary prevention, and recommen-
dations 20 through 22 address which antithrombotic therapies
could be chosen for patients continuing indefinite secondary
prevention.
Recommendations 15, 16, and 17. For patients with un-
provoked DVT and/or PE, the ASH guideline panel suggests
against routine use of prognostic scores (recommendation 15),
D-dimer testing (recommendation 16), or ultrasound to detect residual
vein thrombosis (recommendation 17) to guide the duration of
anticoagulation (conditional recommendations based on very low
certainty in the evidence of effects Å○○○).
Remarks: Indefinite anticoagulation is probably appropriate for the
majority of patients with unprovoked VTE. However, in certain
circumstances, such as when patients are undecided or the
balance between risks and benefits is uncertain, clinicians and
patients may use prognostic scores, D-dimer testing, or ultra-
sound assessment for residual thrombosis from an initial DVT to
aid in reaching a final decision.
Recommendation 18. After completion of primary treatment for
patients with DVT and/or PE provoked by a chronic risk factor, the
ASH guideline panel suggests indefinite antithrombotic therapy
over stopping anticoagulation (conditional recommendation based
on moderate certainty in the evidence of effects ÅÅÅ○).
Remarks: Patients with DVT and/or PE provoked by a transient risk
factor typically do not require antithrombotic therapy after completion
of primary treatment. This recommendation refers to patients with
DVT and/or PE provoked by a chronic persistent risk factor. However,
this recommendation does not apply to patients who have a high risk
for bleeding complications. For guidance on selection of antithrom-
botic therapy after completion of primary treatment, see Recommen-
dation 20. Decisions regarding anticoagulation in individuals with
cancer are discussed in a separate ASH guideline.
Recommendation 19. After completion of primary treatment for
patients with unprovoked DVT and/or PE, the ASH guideline panel
suggests indefinite antithrombotic therapy over stopping anti-
coagulation (conditional recommendation based on moderate
certainty in the evidence of effects ÅÅÅ○).
Remarks: This recommendation does not apply to patients who
have a high risk for bleeding complications. For guidance on
selection of antithrombotic therapy after completion of primary
treatment, see Recommendation 20.
Recommendation 20. For patients with DVT and/or PE who
have completed primary treatment and will continue to receive
secondary prevention, the ASH guideline panel suggests using
Diagnosis of DVT/PE
Initial Management
Decision point for (1) stopping anticoagulation,
or (2) continuing for secondary prevention
Primary Treatment Secondary Prevention
3 to 6 months Planned indefinite duration
First 5-21 days after diagnosis
Figure 1. Time frame of the decisions. Initial management (yellow box) spans the
first 5 to 21 days following diagnosis of a new VTE and includes issues concerning
whether the patient can be treated at home or requires admission to the hospital,
use of thrombolytic therapy, whether an IVC filter needs to be placed, and initial
anticoagulant therapy. Primary treatment continues anticoagulant therapy for 3 to
6 months total and represents the minimal duration of treatment for the VTE. After
completion of primary treatment, the next decision concerns whether anticoagulant
therapy will be discontinued or if it will be continued for secondary prevention of
recurrent VTE. Typically, secondary prevention is continued indefinitely, although
patients should be reevaluated on a regular basis to review the benefits and risks of
continued anticoagulant therapy. Our choice of terminology reflects the distinct
clinical intentions of the different phases of VTE management, linking them to
important clinical decisions addressed in the guidelines, rather than using terms
reflecting the relative duration of therapy.
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anticoagulation over aspirin (conditional recommendation based on
moderate certainty in the evidence of effects ÅÅÅ○).
Recommendation 21. For patients with DVT and/or PE who
have completed primary treatment and will continue VKA therapy
as secondary prevention, the ASH guideline panel recommends
using an international normalized ratio (INR) range of 2.0 to 3.0 over
a lower INR range (eg, 1.5-1.9) (strong recommendation based on
moderate certainty in the evidence of effects ÅÅÅ○).
Recommendation 22. For patients with DVT and/or PE who
have completed primary treatment and will continue with a DOAC for
secondary prevention, the ASH guideline panel suggests using
a standard-dose DOAC or a lower-dose DOAC (conditional recommen-
dation based on moderate certainty in the evidence of effects ÅÅÅ○).
Remarks: Lower-dose DOAC regimens that may be considered
for patients who have completed primary treatment and will
continue with a DOAC include rivaroxaban, 10 mg daily, or
apixaban, 2.5 mg twice daily.
Treatment of recurrent events
Recommendation 23. For patients with breakthrough DVT and/
or PE during therapeutic VKA treatment, the ASH guideline panel
suggests using low-molecular-weight heparin (LMWH) over DOAC
therapy (conditional recommendation based on very low certainty in
the evidence of effects Å○○○).
Remarks: Patients who present with a new VTE event during
therapeutic VKA treatment should be further investigated to identify
potential underlying causes. This recommendation does not apply
to patients who develop breakthrough VTE in the setting of poor
INR control, in whom a DOAC may be a reasonable option.
Recommendation 24a. For patients who develop DVT and/or
PE provoked by a transient risk factor and have a history of previous
unprovoked VTE or VTE provoked by a chronic risk factor, the
ASH guideline panel suggests indefinite antithrombotic therapy
over stopping anticoagulation after completing primary treatment
(conditional recommendation based on moderate certainty in the
evidence of effects ÅÅÅ○).
Recommendation 24b. For patients who develop DVT and/or PE
provoked by a transient risk factor and have a history of a previous VTE
also provoked by a transient risk factor, the ASH guideline panel
suggests stopping anticoagulation after completion of primary treatment
over indefinite antithrombotic therapy (conditional recommendation
based on moderate certainty in the evidence of effects ÅÅÅ○).
Recommendation 25. For patients with a recurrent unprovoked
DVT and/or PE, the ASH guideline panel recommends indefinite
antithrombotic therapy over stopping anticoagulation after comple-
tion of primary treatment (strong recommendation based on
moderate certainty in the evidence of effects ÅÅÅ○).
Remarks (Recommendations 24a, 24b, and 25): For guidance
on selection of antithrombotic therapy after completion of primary
treatment, see Recommendation 20.
Additional management issues
Recommendation 26. For patients with DVT and/or PE with
stable cardiovascular disease (CVD) who initiate anticoagulation and
were previously taking aspirin for cardiovascular risk modification, the
ASH guideline panel suggests suspending aspirin over continuing it
for the duration of anticoagulation therapy (conditional recommen-
dation based on very low certainty in the evidence of effectsÅ○○○).
Remarks: A critical review of the indication for aspirin therapy is
needed at the time anticoagulant therapy is initiated, considering
the increased risk of bleeding vs the potential benefit in terms of
cardiovascular prevention. This recommendation does not apply to
patients with a recent acute coronary event or coronary intervention.
Recommendations 27 and 28. For patients with DVT, with
(Recommendation 27) or without (Recommendation 28) an
increased risk for PTS, the ASH guideline panel suggests against
the routine use of compression stockings (conditional recom-
mendations based on very low certainty in the evidence of effects
Å○○○).
Remarks: Although the majority of patients may not benefit from the
use of stockings to reduce the risk of PTS, stockings may help to
reduce edema and pain associatedwith acute DVT in selected patients.
Introduction
Aim of the guideline and specific objectives
The purpose of this guideline is to provide evidence-based recom-
mendations about the treatment of DVT and PE for patients without
cancer. The target audience includes patients, hematologists, general
practitioners, internists, hospitalists, vascular interventionalists, inten-
sivists, other clinicians, pharmacists, and decision makers. Policy
makers interested in these guidelines include those involved in
developing local, national, or international programs aiming to
reduce the incidence of VTE or to evaluate direct and indirect harms
and costs related to VTE. This document may also serve as the
basis for adaptation by local, regional, or national guideline panels.
Description of the health problem
VTE, which includes DVT and PE, occurs in ;1 to 2 individuals per
1000 each year, or ;300000 to 600000 events in the United
States annually.4 DVT most commonly occurs in the lower extremities
but also affects the upper extremities.5,6 Approximately one third of all
patients with a new diagnosis of VTE have PE, with or without DVT,7-9
and it is estimated that up to a quarter of all patients with PE present
with sudden death.4
The risk for recurrent VTE varies according to whether the initial
event was associated with an acquired risk factor, referred to as
a provoked event, or in the absence of any provoking risk factors,
referred to as an unprovoked event.10 For patients with unpro-
voked VTE, the risks of recurrent VTE after completing a course of
anticoagulant therapy have been estimated to be 10% by 2 years and
.30% by 10 years.11,12 Long-term complications include PTS,
which develops in 20% to 50% of patients after DVT and is severe in
up to 5% of cases,13 and chronic thromboembolic pulmonary
hypertension, which may develop in up to 5% of patients with PE.14
Anticoagulant therapy is very effective at preventing recurrent
VTE but is associated with an increased frequency of bleeding
complications. Major bleeding events may occur in ;1% to 3% of
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patients on VKAs each year, compared to an ;30% lower relative
risk for major bleeding with DOACs.15
Description of the target populations
The incidence of VTE increases with age, ranging from;1 in 10000 in
individuals younger than 20 years of age to as high as ;1 in 100 in
individuals who are 80 years of age and older.16 VTE affects all races
and ethnicities, with black persons having a higher incidence than
white persons in most studies and individuals of Asian descent having
a lower incidence than other races.17-19 Certain acquired character-
istics identify subsets of individuals at higher risk for VTE, including
individuals who are currently or were recently hospitalized, residents in
long-term care facilities, and patients undergoing surgical procedures.4
Time frame of the decisions
Conceptually, the therapeutic management of patients with a new
diagnosis of VTE can be divided into 3 phases: (1) initial management,
which occurs from the time of diagnosis through the first 3 weeks
of therapy; (2) primary treatment, which is a time-limited phase that
typically runs for a minimum of 3 months; and (3) secondary
prevention, which begins after completion of the primary treatment
phase and extends for a prolonged, usually indefinite, period of
time (Figure 1). The specific questions addressed by the guideline
committee are most relevant at specific points in time during
treatment, as summarized below.
Initial management
c Home treatment vs hospital treatment (Recommendations 1 and 2)
c Choice of anticoagulant therapy (Recommendations 3 and 4)
c Use of fibrinolytic therapy (Recommendations 5-9)
c Use of IVC filters (Recommendations 10 and 11)
Primary treatment
c Duration of primary treatment (Recommendations 12-14)
Secondary prevention
c Choice between stopping anticoagulation and indefinite therapy
(Recommendations 15-19)
c Choice of treatment for secondary prevention (Recommenda-
tions 20-22)
The following sections represent topics that may
occur during any phase of treatment
c Management of breakthrough and recurrent DVT/PE (Recom-
mendations 23-25)
c Decision concerning use of aspirin while on anticoagulant
therapy (Recommendation 26)
c Decision concerning use of compression stockings (Recommen-
dations 27 and 28)
Methods
The guideline panel assessed the certainty in the supporting evidence
and developed and graded the recommendations following the
GRADE approach.20-24 The overall guideline-development pro-
cess, including funding of the work, panel formation, management
of conflicts of interest, internal and external review, and organizational
approval, was guided by ASH policies and procedures derived from
the Guideline International Network–McMaster Guideline Development
Checklist (http://cebgrade.mcmaster.ca/guidecheck.html). We devel-
oped our recommendations using the principles outlined by the Institute
of Medicine andGuideline International Network.25-27 An article detailing
the methods used to develop these guidelines has been published.360
Organization, panel composition, planning,
and coordination
The work of this panel was coordinated with 9 other guideline
panels (addressing other aspects of VTE) by ASH and the McMaster
GRADE Centre (funded by ASH under a paid agreement). Project
oversight was provided initially by a coordination panel, which
reported to the ASH Committee on Quality, and then by the
coordination panel chair (A.C.) and vice chair (H.J.S.). ASH vetted
and appointed individuals to the guideline panel. The McMaster
GRADE Centre vetted and retained researchers to conduct
systematic reviews of evidence and to coordinate the guideline-
development process. The membership of the panel and the
GRADE Centre team is described in Supplement 1.
The panel included hematologists, internists, specialists in vascular
medicine, an interventional radiologist, a cardiologist, and pharma-
cists who all had clinical and research expertise in VTE treatment;
methodologists with expertise in evidence appraisal and guideline
development; and 2 patient representatives. The panel chair was
a hematologist with content expertise, whereas the vice chair was
an internist with expertise in guideline development methodology.
In addition to synthesizing evidence systematically, the McMaster
GRADE Centre supported the guideline-development process,
including determining methods, preparing agendas and meeting
materials, and facilitating panel discussions. The panel’s work was
done using Web-based tools (https://www.surveymonkey.com and
https://www.gradepro.org) and face-to-face and online meetings.
Guideline funding and management of conflicts
of interest
Development of these guidelines was wholly funded by ASH,
a nonprofit medical specialty society that represents hematologists.
Most members of the panel were members of ASH. ASH staff
supported panel appointments and coordinated meetings but had
no role in choosing the guideline questions or determining the
recommendations.
Members of the guideline panel received travel reimbursement for
attendance at in-person meetings but received no other payments.
The patient representative was offered, but declined, an honorarium
of $200. Through the McMaster GRADE Centre, some researchers
who contributed to the systematic evidence reviews received salary
or grant support. Other researchers participated to fulfill require-
ments of an academic degree or program.
Conflicts of interest of all participants were managed according to
ASH policies based on recommendations of the Institute of
Medicine and Guideline International Network.26,27 At the time of
appointment, a majority of the guideline panel, including the chair
and the vice chair, had no conflicts of interest, as defined and
judged by ASH (ie, no current material interest in any commercial
entity with a product that could be affected by the guidelines).
Some panelists disclosed new interests or relationships during
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the development process, but the balance of the majority was
maintained.
Before appointment of the panel and during the development
process, panelists disclosed financial and nonfinancial interests.
Members of the VTE Guideline Coordination Panel reviewed the
disclosures and judged which interests were conflicts and should
be managed. Supplement 2 provides the complete “Disclosure of
Interests” forms of all panel members. In Part A of the forms,
individuals disclosed material interests for 2 years prior to
appointment. In Part B, they disclosed interests that were not
primarily financial. Part C summarizes ASH decisions about which
interests were judged to be conflicts. Part D describes new
interests disclosed by individuals after appointment.
Recusal was used to manage conflicts of interest. During
deliberations, panel members with a current direct financial conflict
of interest in a commercial entity with any product that could be
affected by the guidelines were recused from making judgments
about relevant recommendations. The evidence-to-decision (EtD)
framework for each recommendation describes which individuals
were recused from making judgments about each recommendation.
None of the McMaster University–affiliated researchers who
contributed to the systematic evidence reviews or who supported
the guideline-development process had any current material
interest in a commercial entity with any product that could be
affected by the guidelines. Supplement 3 provides the complete
“Disclosure of Interests” forms of researchers who contributed to
these guidelines.
Formulating specific clinical questions and
determining outcomes of interest
We initially brainstormed clinical issues relevant for VTE manage-
ment. Then, using an on-line survey developed with SurveyMonkey
(https://www.surveymonkey.com) and in an online meeting, we
prioritized 32 clinical questions. We addressed 28 such questions
in this guideline. Three questions related to clinical issues were
seen more frequently for cancer patients and, therefore, will be
addressed in the chapter about management of VTE for patients
with cancer. One additional question was dropped at the in-person
panel meeting because we considered that the clinical issue was
sufficiently addressed by another recommendation (Table 1).
Panelists then selected outcomes of interest for each question
a priori, following an approach described in detail elsewhere.28 In
brief, the panel first brainstormed all possible outcomes before
rating the relative importance for decision making of each. During
this rating process, the panel used definitions of the outcomes
(“marker states”) that were developed for these guidelines. The
panel rated the following outcomes as critical for clinical decision
making across questions: mortality, PE, proximal DVT, and major
bleeding. Additionally, for the questions related to thrombolysis in
DVT and the use of compression stockings, the panel also rated the
incidence of PTS as critical.
Evidence review and development
of recommendations
For each guideline question, the McMaster GRADE Centre
prepared a GRADE EtD framework, using the GRADEpro Guideline
Development Tool (www.gradepro.org). The EtD table summarized
the results of systematic reviews of the literature that were
Table 1. Patient populations and interventions in VTE treatment
Initial management: up through the first week
Home treatment vs hospital treatment for patients with uncomplicated DVT
Home treatment vs hospital treatment for patients with PE and low risk for complication
DOAC vs VKA for patients with VTE
One DOAC vs another DOAC for patients with VTE
Thrombolytic therapy plus anticoagulation vs anticoagulation alone for patients with
extensive proximal DVT
Thrombolytic therapy plus anticoagulation vs anticoagulation alone for patients with PE
and hemodynamic compromise
Thrombolytic therapy plus anticoagulation vs anticoagulation alone for patients with
submassive PE
Catheter-directed thrombolysis vs systemic thrombolysis for patients with DVT
Catheter-directed thrombolysis vs systemic thrombolysis for patients with PE
IVC filter plus anticoagulation vs anticoagulation alone for patients with DVT and
significant cardiopulmonary disease
IVC filter plus anticoagulation vs anticoagulation alone for patients with PE and
hemodynamic compromise
Primary treatment: treatment of the acute event
Longer course of anticoagulation vs shorter course for patients with VTE related to
a transient risk factor
Longer course of anticoagulation vs shorter course for patients with VTE related to
a chronic risk factor
Longer course of anticoagulation vs shorter course for patients with unprovoked VTE
Secondary prevention: continuation of anticoagulation after primary treatment
Prognostic scores vs no prognostic score to decide duration of treatment for patients
with unprovoked VTE
D-dimer vs no D-dimer to decide duration of treatment for patients with unprovoked VTE
Ultrasound vs no ultrasound to decide duration of treatment for patients with unprovoked VTE
Indefinite anticoagulation vs discontinuation for patients with VTE related to a chronic risk
factor
Indefinite anticoagulation vs discontinuation for patients with unprovoked VTE
Aspirin vs anticoagulation for patients with VTE who are going to continue antithrombotic
therapy
Lower-target INR vs standard target for patients with VTE who are going to continue on
anticoagulation
Lower-dose DOAC vs standard-dose DOAC for patients with VTE who are going to
continue on anticoagulation
Treatment of recurrent events
DOAC vs LMWH for patients with breakthrough VTE during treatment with VKA
Indefinite anticoagulation vs discontinuation for patients with recurrent VTE related to
a transient risk factor
Indefinite anticoagulation vs discontinuation for patients with recurrent unprovoked VTE
Additional management issues
Continuation of aspirin vs discontinuation for patients with VTE who initiate
anticoagulation
Compression stockings plus anticoagulation vs anticoagulation alone for patients with DVT
Compression stockings plus anticoagulation vs anticoagulation alone for patients with
DVT and high risk for PTS
Excluded questions and reason for exclusion
Anticoagulation vs no anticoagulation for patients with CVC-associated DVT (addressed
in future guideline document from ASH)
Removal of CVC vs maintaining CVC for patients with CVC-associated DVT (addressed
in future guideline document from ASH)
Anticoagulation vs no anticoagulation for patients with incidental PE (addressed in future
guideline document from ASH)
One DOAC vs another DOAC for patients with VTE during treatment with VKA (already
addressed by related question above, “One DOAC vs another DOAC for patients with VTE”)
CVC, central venous catheter.
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conducted for these guidelines. Each EtD table addressed the
effects of interventions, resource use (cost effectiveness), values
and preferences (relative importance of outcomes), equity, accept-
ability, and feasibility. The guideline panel reviewed draft EtD tables
before, during, or after the guideline panel meeting and made
suggestions for correction and identified missing evidence.
To estimate the effect of the interventions covered in this guideline,
we conducted a search for systematic reviews on MEDLINE,
Embase, the Cochrane Library, and Epistemonikos from their
respective dates of inception to January 2017. We also conducted
a search of potentially missed trials in MEDLINE and Embase from
January 2014 to January 2017. Before the publication of this
guideline, we updated the searches to January 2019 (detailed
search strategies are described in Supplement 4). Additionally,
panel members were asked to suggest any studies that may have
been missed and fulfilled the inclusion criteria for the individual
questions. We excluded trials evaluating the effects of the direct
thrombin inhibitor ximelagatran, given that this drug was withdrawn
from the market because of safety concerns in those countries
where it had received approval.
We used existing systematic reviews as a way to identify rele-
vant trials, but we conducted our own meta-analyses for all of
the questions following the principles outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (https://training.
cochrane.org/handbook). We meta-analyzed the data using a ran-
dom effects model according to the method of Mantel-Haenszel.
We explored heterogeneity with the x2 test and with the I2 statistic.
When significant heterogeneity was detected (I2 $ 50%), we
explored differences among trials in the included population, the
way that interventions were used, outcomes measurement, and risk
of bias.
All of the meta-analyses were conducted using RevMan (version
5.3 Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014). Publication bias was assessed graphically by
evaluating symmetry in the funnel plots. To estimate the absolute
effect of the intervention, we calculated the risk difference by
multiplying the pooled risk ratio and the baseline risk of each
outcome. As baseline risk, we used the median of the risks observed
in control groups of the included trials. Additionally, when possible,
we used the baseline risk observed in large observational studies.
Certainty in the body of evidence was assessed (also known as
quality of the evidence or confidence in the estimated effects)
following the GRADE approach. We made judgments regarding
risk of bias, precision, consistency, directness, and likelihood of
publication bias and categorized the certainty in the evidence into 4
levels ranging from very low to high.22,23 In addition, we conducted
systematic searches to identify evidence related to baseline risks,
values, preferences, and costs and summarized findings within the
EtD tables.
During a 2-day in-person meeting, followed by online communica-
tion and conference calls, the panel developed clinical recommen-
dations based on the evidence summarized in the EtD tables. For
each recommendation, the panel took a population perspective and
came to consensus on the following: the certainty in the evidence,
the balance of benefits and harms of the compared management
options, and the assumptions about the values and preferences
associated with the decision. The guideline panel also explicitly took
into account the extent of resource use associated with alternative
management options.
The panel agreed on recommendations (including direction and
strength), remarks, and qualifications by consensus or, in rare
instances, by voting (an 80% majority was required for a strong
recommendation) based on the balance of all desirable and
undesirable consequences. In such circumstances, the result
of the voting was recorded on the respective EtD table. The
final guidelines, including recommendations, were reviewed and
approved by all members of the panel.
Interpretation of strong and
conditional recommendations
The recommendations are labeled as “strong” or “conditional”
according to the GRADE approach. The words “the guideline
panel recommends” are used for strong recommendations and
“the guideline panel suggests” are used for conditional recom-
mendations. Table 2 provides GRADE’s interpretation of strong
and conditional recommendations by patients, clinicians, health
care policy makers, and researchers.
Document review
All panel members reviewed the recommendations and remarks.
The full EtD tables (including recommendations) were made
available from 30 November 2018 to 19 January 2019 for external
review by stakeholders, including allied organizations, medical profes-
sionals, patients, and the general public. We received comments and
additional references from 17 individuals and organizations. The final
document and supplemental material were revised to address
pertinent inputs, but no changes were made to recommendations.
The guidelines were approved by the ASH Guideline Oversight
Subcommittee and Committee on Quality on 18 February 2020
and by the ASH Executive Committee on 26 February 2020 and
then subjected to peer review.
How to use these guidelines
These guidelines are primarily intended to help clinicians make
decisions about treatment alternatives. Other purposes are to
inform policy, to promote education and advocacy, and to state
future research needs. They may also be used by patients. These
guidelines are not intended to serve or be construed as a standard
of care. Clinicians must make decisions on the basis of the clinical
presentation of each individual patient, ideally through a shared
decision-making process that considers the patient’s values and
preferences with respect to the anticipated outcomes of the
chosen option. Decisions may be constrained by the realities of
a specific clinical setting and local resources, including, but not
limited to, institutional policies, time limitations, or availability of
treatments.
These guidelines may not include all appropriate methods of care
for the clinical scenarios described. As science advances and new
evidence becomes available, recommendations may become out-
dated. Following these guidelines cannot guarantee successful
outcomes. ASH does not warrant or guarantee any products
described in these guidelines.
Statements about the underlying values and preferences, as well as
qualifying remarks accompanying each recommendation, are its
integral parts and serve to facilitate more accurate interpretation.
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They should never be omitted when recommendations from these
guidelines are quoted or translated. The use of these guidelines is
also facilitated by the links to the EtD frameworks and interactive
summary of findings tables in each section.
Recommendations
Initial management: up through the first week
Recommendation 1
For patients with uncomplicated DVT, the ASH guideline panel
suggests offering home treatment over hospital treatment
(conditional recommendation based on low certainty in the
evidence of effects ÅÅ◯◯).
Remarks: This recommendation does not apply to patients
who have other conditions that would require hospitalization,
have limited or no support at home, and cannot afford medi-
cations or have a history of poor compliance. Patients with limb-
threatening DVT or at high risk for bleeding and those requiring
IV analgesics may benefit from initial treatment in the hospital.
Summary of the evidence
We identified 1 systematic review29 and 7 randomized controlled
trials (RCTs) (n 5 1922).30-36 Trials included individuals with an
objectively confirmed symptomatic DVT. Participants were random-
ized to home or hospital management with LMWH, warfarin (both
can be used in either setting), or unfractionated heparin (UFH)
(which is generally used in hospital only). Four RCTs30,33-35 had
partial hospital treatment for some participants in the home group,
ranging from a mean of 1 to 3 days, compared with 6.5 to 9.6 days
in the hospital treatment arm. Trials with a hospital stay $3 days
prior to home treatment were excluded. All seven trials reported
the effect of antithrombotic therapy on mortality and PE and
assessed the risk of major bleeding. Six trials reported the effect




Treating patients with DVT at home, rather than in the hospital,
reduced the risk of PE (relative risk [RR], 0.64; 95% confidence
interval [CI], 0.44-0.93; absolute risk reduction [ARR], 25 fewer per
1000 patients; 95% CI, 38 fewer to 5 fewer; moderate-certainty
evidence) and the risk of subsequent DVT (RR, 0.61; 95% CI, 0.42-
0.90; ARR, 29 fewer per 1000 patients; 95% CI, 43 fewer to 7
fewer; moderate-certainty evidence). In a low-risk population,37
home treatment reduces the risk of PE (2 fewer per 1000 patients
with 95% CI of 4 fewer to 0 fewer; moderate-certainty evidence)
and proximal DVT (4 fewer per 1000 patients with 95% CI of 6
fewer to 1 fewer; moderate-certainty evidence) as well. Home
treatment was associated with a reduction in long-term mortality
(RR, 0.72; 95% CI, 0.45-1.15; ARR, 13 fewer per 1000 patients;
95% CI, 25 fewer to 7 more; low-certainty evidence), although this
was not statistically significant. When considering the mortality at
90 days for patients with DVT treated in the hospital as the baseline
risk,37 treating at home instead of treating in the hospital may lead to
a reduction of 19 fewer deaths per 1000 patients (95% CI, 37
fewer to 10 more; low-certainty evidence).
Harms and burden
The risk of major bleeding may be lower when treating patients at
home rather than in the hospital (RR, 0.67; 95% CI, 0.33-1.36;
ARR, 6 fewer per 1000 patients; 95% CI, 13 fewer to 7 more; low-
certainty evidence). In populations with a low bleeding risk,37
treating at home instead of treating in the hospital may lead to
a reduction of 5 fewer bleeding events per 1000 patients (95% CI,
11 fewer to 6 more; low-certainty evidence).
Different types of burdens are associated with both interventions.
Hospital stay is associated with procedures, risk, and burden for
patients. Home treatment is associated with increased burden on
patients and family (eg, self-injection of LMWH and/or clinic visits
for INR monitoring).
Certainty in the evidence of effects
The certainty in the evidence was judged low for mortality because
of the serious risk of bias and imprecision and moderate for PE and
proximal DVT because of the serious risk of bias. Of 7 RCTs,
Table 2. Interpretation of strong and conditional recommendations
Implications for: Strong recommendation Conditional recommendation
Patients Most individuals in this situation would want the recommended
course of action, and only a small proportion would not.
The majority of individuals in this situation would want the
suggested course of action, but many would not. Decision aids
may be useful in helping patients to make decisions consistent
with their individual risks, values, and preferences.
Clinicians Most individuals should follow the recommended course of action.
Formal decision aids are not likely to be needed to help individual
patients make decisions consistent with their values and
preferences.
Different choices will be appropriate for individual patients, and
clinicians must help each patient to arrive at a management
decision consistent with the patient’s values and preferences.
Decision aids may be useful in helping individuals to make
decisions consistent with their individual risks, values, and
preferences.
Policy makers The recommendation can be adopted as policy in most situations.
Adherence to this recommendation, according to the guideline,
could be used as a quality criterion or performance indicator.
Policy making will require substantial debate and involvement of
various stakeholders. Performance measures should assess
whether decision making is appropriate.
Researchers The recommendation is supported by credible research or other
convincing judgments that make additional research unlikely to
alter the recommendation. On occasion, a strong
recommendation is based on low or very low certainty in the
evidence. In such instances, further research may provide
important information that alters the recommendations.
The recommendation is likely to be strengthened (for future
updates or adaptation) by additional research. An evaluation of
the conditions and criteria (and the related judgments, research
evidence, and additional considerations) that determined the
conditional (rather than strong) recommendation will help to
identify possible research gaps.
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allocation was clearly concealed in 3 (unclear in 3 and probably
unconcealed in 1 with unspecified opaque envelope), outcome
adjudicators were clearly blinded in the 2 largest RCTs (unclear in
remaining 5), and missing data were significant in 1 small RCT.
Considering that the CIs around the absolute estimates likely
include values suggesting substantial benefit and substantial harm,
we also rated down the certainty in the evidence because of
imprecision for mortality. For major bleeding, the certainty in the
evidence was judged low because of serious risk of bias and
imprecision.
Other EtD criteria and considerations
We considered that avoidance of PE, DVT, and bleeding was
critical for patients. However, there are likely important variations in
how individual patients may value thrombosis vs bleeding risk.
We identified 5 reports based on real-world data that com-
pared the treatment cost of home management vs hospital
management.30,32,38-40 All reports showed that home manage-
ment is cost saving compared with inpatient management.
LMWH was used in these reports for home management. We
also identified 5 reports that compared the cost and effective-
ness of home treatment and hospital treatment for patients with
DVT or for VTE patients in general. One economic evaluation in
a Canadian setting based on a decision tree suggests home
treatment as cost effective compared with hospital manage-
ment.41 The other 4 reports suggest that home management
leads to cost savings without compromising outcome effects
and safety. LMWH was used for home management in all of
these studies, whereas UFH was primarily used in hospital-
based management.42-45
Health equity may decrease in rural areas or settings with limited
health care access. In health systems with good primary care, home
treatment is feasible and safe. In health systems with poor primary
care, home treatment may reduce equity.
The panel considered home treatment acceptable and feasible in
most cases, although economic incentives might favor in-hospital
treatment in fee-for-service systems.
Health equity may be reduced for selected groups of patients
based on observational studies evaluating outcomes after VTE
treatment, including uninsured patients,46 African American
patients,47 female patients,48 and older patients.49 Reductions
in health equity for $1 of these groups of patients may be
present for all of the recommendations considered in this
guideline document.
Conclusions and implementation considerations
Although our analysis suggests that patients with uncomplicated
DVT treated at home rather than in the hospital have a lower risk for
PE and DVT, as well as a lower risk for major bleeding, the evidence
in support of these observations is of low quality, making the
recommendation conditional. The decision to treat a patient with an
isolated DVT at home needs to be individualized, and certain
patients would be more appropriately treated in the hospital,
including patients with massive DVT (defined as being associated
with severe pain, swelling of the entire limb, phlegmasia cerulea
dolens, or limb ischemia), at high risk for anticoagulant-related
bleeding, or with major comorbidities.50 Social factors, such as
limited home support, history of noncompliance, and limited
financial resources, may also favor the hospital setting for the initial
phase of treatment.
Recommendation 2
For patients with PE with low risk for complications, the ASH
guideline panel suggests offering home treatment over hospital
treatment (conditional recommendation based on very low
certainty in the evidence of effects Å○○○).
Remarks: Clinical prediction scores for PE severity have, at
best, a moderate ability to predict patient outcomes and,
therefore, do not replace clinical judgment. However, they may
help to select patients with PE at low risk for complications. The
PESI1 and simplified PESI2 have been most widely validated.
This recommendation does not apply to patients who have
other conditions that would require hospitalization, have limited
or no support at home, and cannot afford medications or have
a history of poor adherence. Patients with submassive or
massive PE or a high risk for bleeding or requiring IV analgesics
may benefit from initial treatment in the hospital.
Summary of the evidence
We identified 5 systematic reviews,51-55 2 RCTs56,57 (n 5 451),
and 3 observational studies (n 5 451).58-60 The RCTs included
participants who had an objectively confirmed low-risk acute PE.
In 1 trial, participants were randomized to home or hospital
management; regardless of the treatment arm, all participants
received subcutaneous enoxaparin, 1 mg/kg twice daily, followed
by VKA.56 In another trial,57 patients were randomized to early
discharge on 15 mg of oral rivaroxaban twice daily, followed by
20 mg of oral rivaroxaban once daily for 90 days, whereas the
inpatient group received local standard of care, which included any
US Food and Drug Administration–approved anticoagulant strat-
egy. In both trials, the outpatient treatment groups were discharged
within 24 hours after randomization. These trials reported the
effect of antithrombotic therapy on mortality, VTE, and major
bleeding. Additionally, 3 observational studies reported mortal-
ity and major bleeding at 3 months follow-up, and 1 reported




Analysis of RCTs showed that treating patients with PE and a low
risk for complications at home, rather than in the hospital, may
reduce the risk of mortality at 30 days (RR, 0.33; 95% CI, 0.01-
7.98; ARR, 2 fewer per 1000 patients, 95% CI, 2 fewer to 16 more
for low-risk PE patients treated in the hospital51; low-certainty
evidence) and 90 days (RR, 0.98; 95% CI, 0.06-15.58; ARR,
0 fewer per 1000 patients, 95%CI, 7 fewer to 108 more for low-risk
PE patients treated in the hospital51; low-certainty evidence),
although CIs included significant benefit and harm. The analyses of
observational studies also suggested a possible small reduction in
long-term mortality at 90 days of follow-up (RR, 0.81; 95%CI, 0.42-
1.58; ARR, 18 fewer per 1000 patients; 95% CI, 56 fewer to 56
more; very-low-certainty evidence) or PE (RR, 0.72; 95% CI, 0.07-
7.70; ARR, 9 fewer per 1000 patients; 95% CI, 30 fewer to 216
more; very-low-certainty evidence).

















L user on 27 O
ctober 2020
Harms and burden
Evidence from the included RCTs demonstrates that treating
patients with PE at low risk for complications at home, rather than in
the hospital, may increase the risk of subsequent PE (RR, 2.95;
95% CI, 0.12-71.85; ARR, 23 more per 1000 patients; 95% CI, 11
fewer to 850 more; low-certainty evidence) and major bleeding (RR,
6.88; 95%CI, 0.36-132.14; ARR, 59 more per 1000 patients; 95%
CI, 6 fewer to 1000 more; low-certainty evidence), although CI
included significant benefit and harm. Observational studies also
demonstrated a potential increase in major bleeding risk (RR, 2.68;
95% CI, 0.11-63.45; ARR could not be calculated; very-low-
certainty evidence).
Certainty in the evidence of effects
The certainty in the evidence from the included RCTs was judged
low for short-term and long-term mortality, PE, DVT, and major
bleeding because of the small number of events and wide CI that
covered appreciable benefit and harm. The certainty in the evidence
from observational studies was judged very low for PE and major
bleeding because of the inappropriate adjustment for additional
factors, the lack of reporting for the assessment of outcomes and
adequacy of follow-up in most studies, the small number of events
among the included studies, and wide CIs that covered appreciable
benefit and harm. The certainty in the evidence from observational
studies was judged very low for long-term mortality for the same
reasons as well as a high degree of inconsistency among the
pooled estimates. In addition, 1 of the studies included patients who
had active or palliative cancer and may have had a higher risk for
dying than the other patient populations included in the systematic
review.
Other EtD criteria and considerations
We considered that avoidance of PE, DVT, and major bleeding
was critical for patients. However, there is likely important variation
in how individual patients may value the risk of thrombosis vs the risk
of bleeding.
We identified 5 reports based on real-world data that compared the
cost of home management vs hospital management.30,32,38-40 All
reports showed that home management is cost saving compared
with inpatient management. LMWH was used in these reports for
home management. We also identified 5 reports that compared the
cost and effectiveness of home treatment and hospital treatment for
patients with DVT or for VTE patients, in general. One economic
evaluation in a Canadian setting based on a decision tree suggests
that home treatment is cost effective compared with hospital
management.41 The other 4 reports suggest that home manage-
ment leads to cost savings without compromising effects and
safety. In all of these studies, LMWH was used for home
management, whereas UFH was primarily used in hospital
management.42-45
Health equity may decrease in rural areas or settings with limited
health care access. In health systems with good primary care, home
treatment is feasible and safe. In health systems with poor primary
care, home treatment may reduce equity.
The panel considered home treatment acceptable and feasible in
most cases, although economic incentives might favor in-hospital
treatment in fee-for-service systems.
Conclusions and implementation considerations
Several studies have demonstrated that patients with PE who are at
low risk for complications can be effectively and safely treated at
home; however, the quality of evidence in support of this
recommendation is of very low certainty, making this a conditional
recommendation. Most patients with PE continue to be admitted to
the hospital for treatment initiation, including a significant proportion
of individuals who could be treated at home.61 Multiple factors likely
contribute to the selection of the treatment setting, and implementa-
tion of an outpatient treatment program for PE requires several steps.
First, there needs to be a systematic approach to determine which
individuals with PE can be considered for outpatient management.61
Several assessment tools that use baseline clinical information to
identify patients at low risk for adverse events during the first few
months after diagnosis of PE have been developed, but these
prognostic risk scores have not been evaluated prospectively for
identification of patients with PE who can be safely treated at home.
Clinical assessment and judgment are still required for identifying
patients with PE who are appropriate for home management. Second,
it is essential that risk stratification be performed quickly, shortly after
the patient has been diagnosedwith PE, to facilitate discharge from the
emergency department and avoid hospitalization. Lastly, and most
importantly, an infrastructure to provide outpatient PE treatment needs
to be established to ensure that patients can be followed closely. As
with outpatient DVT treatment, social factors, such as limited home
support, history of nonadherence, and limited financial resources,
would favor the hospital setting for the initial phase of treatment. Well-
designed prospective studies that confirm the safety and efficacy of
home treatment for selected patients with PE would be helpful, but the
barriers listed above would need to be addressed prior to more
widespread adoption of this recommendation.
Recommendation 3
For patients with DVT and/or PE, the ASH guideline panel sug-
gests using DOACs over VKAs (conditional recommendation
based on moderate certainty in the evidence of effects ÅÅÅ○).
Remarks: This recommendation may not apply to certain
subgroups of patients, such as those with renal insufficiency
(creatinine clearance ,30 mL/min), moderate to severe liver
disease, or antiphospholipid syndrome.
Summary of the evidence
We identified 24 systematic reviews62-85 and 12 randomized trials86-97
(n 5 28876). Trials included individuals with an objectively confirmed
symptomatic proximal DVT or PE. Participants were randomized
to DOACs or to an initial treatment with LMWH (5-10 days)
with dose-adjusted warfarin (INR range, 2.0-3.0). Dabigatran
and edoxaban were also administered after an initial treatment
of 5 to 10 days with LMWH, whereas rivaroxaban and apixaban
were administered without initial parenteral anticoagulants. The
length of the anticoagulation varied across trials from 3 to 12
months. Individuals with significant renal impairment, as indicated
by an estimated creatinine clearance ,25 mL/min (apixaban) or
30 mL/min (all other DOACs) and patients at high risk for bleeding
were excluded. The EtD framework is shown online at: https://
guidelines.gradepro.org/profile/B7293C21-767F-B3F8-8BB2-
A4E5173CDAC3.
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Benefits
The use of a DOAC instead of a VKA for patients with VTE does
not impact mortality (RR, 0.99; 95% CI, 0.85-0.15; ARR, 0 fewer
per 1000 patients; 95% CI, 6 fewer to 6 more; moderate-
certainty evidence) or the risk of PE (RR, 0.97; 95% CI, 0.77-
1.23; ARR, 1 fewer per 1000 patients; 95% CI, 5 fewer to 5
more; moderate-certainty evidence). However, we did observe
a reduction in the risk of DVT (RR, 0.80; 95% CI, 0.59-1.09;
ARR, 5 fewer per 1000 patients; 95% CI, 11 fewer to 2 more;
moderate-certainty evidence), although this was not statistically
significant.
Harms and burden
The use of a DOACwas associatedwith a reduction in the risk of major
bleeding (RR, 0.63; 95% CI, 0.47-0.84; ARR, 6 fewer per 1000
patients; 95% CI, 9 fewer to 3 fewer; high-certainty evidence). In
populations with a high risk for bleeding,98 the use of a DOAC instead
of a VKA may lead to a reduction of 8 fewer bleeding events per 1000
(95% CI, 11 fewer to 3 fewer; high-certainty evidence).
Additionally, given that the DOACs do not require frequent dose
adjustment, monitoring of the INR, or dietary restrictions, they are
probably associated with a lower burden for patients, particularly
during anticoagulant initiation.
Certainty in the evidence of effects
The certainty in the evidence was judged moderate for mortality,
PE, and DVT because of imprecision, given that the CI around the
absolute estimates likely crossed the thresholds that patients would
consider important. Therefore, it was not possible to completely rule
out a small difference between the alternatives on such outcomes.
For major bleeding, the certainty in the evidence was judged high.
Other EtD criteria and considerations
We considered that avoidance of PE, DVT, and major bleeding was
critical for patients. However, there is likely an important variation in how
individual patients value the risk of thrombosis vs the risk of bleeding.
We identified 5 cost comparisons between DOACs and VKA for
patients with VTE. Four reports suggested that a DOAC is cost
saving compared with warfarin,99-102 and 1 study found an
equivalent cost between a DOAC and a VKA.103 Also, we identified
14 economic evaluations comparing the cost and effectiveness of
DOACs vs VKA. All of them suggested that DOACs are cost-
effective relative to VKA.100,104-116
Finally, we considered DOACs to be acceptable and feasible to
implement in most scenarios. However, given their cost, some
patients might not be able to afford them.
Conclusions and implementation considerations
The ASH VTE treatment guideline panel has provided a condi-
tional recommendation for the use of DOACs over VKAs as
treatment for patients with a new diagnosis of VTE. Although the
evidence supporting a reduced risk for bleeding with the use of
a DOAC compared with a VKA was of high certainty, the lack
of benefit for the VTE outcomes resulted in the conditional
recommendation.
Several additional variables need to be taken into consider-
ation when selecting an anticoagulant for an individual patient.
For example, patients who require medications that are
inhibitors or inducers of P-glycoprotein, or strong inhibitors
or inducers of cytochrome P450 3A4 (CYP3A4) enzymes,
should consider treatment with a VKA or LMWH rather than
a DOAC, given the interactions of these medications with
DOACs. Renal and/or hepatic insufficiency also needs to be
taken into consideration prior to selecting an anticoagu-
lant. Other variables that may impact the choice of anticoag-
ulant therapy for individual patients include the cost of the
DOACs and patient preference for once- or twice-daily dosing.
Finally, patients with antiphospholipid antibody syndrome,
bariatric surgery, short gut, or other conditions that may influ-
ence medication absorption, as well as patients at extremes
of body weight, are not optimal candidates for DOACs. See the
ASH guideline on optimal anticoagulant therapy for additional
details.117
Anticoagulant therapy needs to be started during the initial
management phase of VTE treatment and continued through the
primary treatment phase for all patients with VTE who do not
have a contraindication to anticoagulant therapy (Figure 1). For
patients who will be treated with a VKA, initiation must be
overlapped with UFH or LMWH for a minimum of 5 days and
a therapeutic INR is achieved for 24 hours, at which time the
heparin is discontinued. For patients who will be treated with
dabigatran or edoxaban, pretreatment with UFH or LMWH for
up to 5 to 10 days is needed before switching to the DOAC. For
patients treated with rivaroxaban or apixaban, there is no need
for pretreatment with UFH or LMWH. In contrast, a higher dose
is administered for the 3 three weeks of therapy with rivaroxaban
and for the first week of therapy with apixaban. These
differences can be particularly important for those patients
being considered for treatment at home rather than in the
hospital.
Recommendation 4
For patients with DVT and/or PE, the ASH guideline panel does
not suggest 1 DOAC over another (conditional recommenda-
tion based on very low certainty in the evidence of comparative
effects Å○○○).
Remarks: Factors such as a requirement for lead-in parenteral
anticoagulation, once- vs twice-daily dosing, and out-of-pocket
cost may drive the selection of specific DOACs. Other factors,
such as renal function, concomitant medications (eg, need for
a concomitant drug metabolized through CYP3A4 enzymes or
P-glycoprotein), and the presence of cancer, may also impact
DOAC choice.
Summary of the evidence
We did not find any systematic reviews or randomized trials
comparing different DOACs head to head. We conducted a sub-
group analysis of the evidence of DOACs vs VKAs86-97 and found
no interaction between the specific agent used and the risk of
mortality, PE, symptomatic DVT, or major bleeding. The EtD
framework is shown online at: https://guidelines.gradepro.org/
profile/FFEF27C2-5C33-BB1B-B096-9624FCBB0456.
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Benefits, harms, and burden
Given the lack of evidence of the comparative effectiveness of
different DOACs, we were unable to estimate the benefits and
harms of specific agents.
Certainty in the evidence of effects
The certainty in the evidence was judged very low for all of the
relevant outcomes, given that only indirect evidence was available.
Other EtD criteria and considerations
Given the lack of direct evidence, economic evaluation assessing
the cost utility of different DOACs is based on assumptions and
indirect observations.
In addition to cost, factors like coverage by health insurers, dosing
(once vs twice daily), and requirement of initial use of LMWH will
probably influence patient preferences.
Conclusions and implementation considerations
For patients who will be treated with a DOAC, the ASH guideline panel
does not suggest 1medication over another given the very low certainty
in the evidence on comparative effects. However, for patients who will
be taking a DOAC, there are differences that should be taken into
consideration.118 Renal insufficiency is a variable that needs to be taken
into consideration when selecting a DOAC, because the 4 agents that
are currently available differ in the proportion of drug that is cleared by
the kidneys, ranging from;80% for dabigatran to 25% for apixaban.118
Ongoing studies evaluating apixaban use for patients with end-stage
renal disease will further clarify its safety in this population. DOACs
should be avoided as a class for patients with severe hepatic disease
associated with coagulopathy; however, there are differences in which
drugs can be used for patients with milder hepatic insufficiency, and
dabigatran is least reliant on hepatic clearance. Other variables that may
be important for the individual patient include whether the medication
must be taken with food, preference for once-daily vs twice-daily dosing,
the need to use a pill box, or the need to crush tablets prior to
administration. Prospective research studies comparing different
DOACs would be valuable in selected patient populations, such as
individuals with renal insufficiency, liver disease, or morbid obesity.
Recommendation 5
In most patients with proximal DVT, the ASH guideline panel
suggests anticoagulation therapy alone over thrombolytic therapy
in addition to anticoagulation (conditional recommendation based
on low certainty in the evidence of effects ÅÅ○○).
Remarks: Thrombolysis is reasonable to consider for patients
with limb-threatening DVT (phlegmasia cerulea dolens) and for
selected younger patients at low risk for bleeding with symp-
tomatic DVT involving the iliac and common femoral veins
(higher risk of more severe PTS). Patients in these categories
who value rapid resolution of symptoms, are averse to the
possibility of PTS, and accept the added risk of major bleeding
may prefer thrombolysis. The use of thrombolysis should be
rare for patients with DVT limited to veins below the common
femoral vein.
Summary of the evidence
We identified 11 systematic reviews119-129 and 19 randomized trials
(n 5 1944).130-148 Trials included individuals with objectively
confirmed symptomatic proximal DVT. Participants were randomized
to thrombolytic therapy in addition to anticoagulation or to anti-
coagulation alone. In general, thrombolytics were systemically
infused, except in 4 trials, including the recently published ATTRACT
trial, in which thrombolytics were catheter directed133,134,146,148 and
2 trials in which thrombolytics were locoregionally infused.141,142 The
EtD framework is shown online at: https://guidelines.gradepro.org/
profile/8C3F2B15-9D6F-8618-8A41-444E83A9B780.
Benefits
The use of thrombolytics for patients with DVT may reduce the risk of
PTS (RR, 0.70; 95% CI, 0.59-0.83; ARR, 169 fewer per 1000
patients; 95% CI, 96 fewer to 231 fewer; low-certainty evidence)
without significantly impacting mortality (RR, 0.77; 95% CI, 0.26-2.28;
ARR, 0 fewer per 1000 patients; 95% CI, 1 fewer to 1 more; low-
certainty evidence), the risk of PE (RR, 1.33; 95%CI, 0.71-2.46; ARR,
5 more per 1000 patients; 95% CI, 4 fewer to 21 more; low-certainty
evidence), or the risk of DVT (RR, 0.99; 95% CI, 0.56-1.76; ARR, 1
fewer per 1000 patients; 95% CI, 57 fewer to 99 more; low-certainty
evidence).
Harms and burden
The use of thrombolytics for patients with VTE (PE or DVT) was
associated with an increase in the risk of major bleeding (RR, 1.89;
95% CI, 1.46-2.46; ARR, 31 more per 1000 patients; 95% CI, 16
more to 51 more; high-certainty evidence) and intracranial bleeding
(RR, 3.17; 95% CI, 1.19-8.41; ARR, 7 more per 1000 patients;
95% CI, 1 more to 22 more; moderate-certainty evidence).
We tested whether the risk of major bleeding varied with the different
routes of administration (ie, systemic vs locoregional vs catheter
directed) and found that major bleeding was increased, regardless of
the strategy used (RR for systemic infusion, 1.74; RR for catheter-
directed infusion, 3.77; RR for locoregional infusion, 4.14).
Certainty in the evidence of effects
The certainty in the evidence was judged as low for mortality, PE,
and DVT because of risk of bias (none of the included trials were
blinded) and imprecision (CI around the absolute estimates likely
crossed the thresholds that patients would consider important).
The effect on PTS was considered precise, but as before, we rated it
down by risk of bias. Additionally, we also rated down the certainty in
the evidence by inconsistency, given that 7 of the included studies
reported significant PTS reduction, whereas 1 single trial (ATTRACT
trial)146 reported the absence of a significant effect (I2 5 57%).
Finally, the certainty in the evidence for major bleeding was judged
as high.
Other EtD criteria and considerations
The panel considered that avoidance of PE, DVT, PTS, and major
bleeding was critical for patients. However, the more relevant trade-
off for patients may be between the risk of PTS and the risk of major
bleeding. We judged that there is probably a large variation in what
informed patients may choose.
Because only catheter-directed thrombolysis is available in the
United States, implementing the procedure would probably result in
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large costs, which, in turn, will probably reduce equity and limit its
acceptability and feasibility.
Conclusions and implementation considerations
PTS may develop in up to 30% to 50% of patients following
the development of a proximal DVT,149,150 and this may be severe in
5% to 10% of patients.3,150 Thrombolytic therapy has been shown
to result in a more rapid and complete lysis of thrombus than
anticoagulant therapy alone, but relatively few studies have linked
radiographic improvements to clinical outcomes. Based on the low
certainty in the evidence, the ASH guideline panel has suggested
against the addition of thrombolytic therapy to anticoagulation for
patients with proximal DVT. However, as noted above, certain patients
with acute DVT might benefit from the addition of thrombolytic therapy,
as determined by the severity of symptoms, location and extent of the
thrombosis, and/or initial response to anticoagulant therapy. The
decision to proceed with thrombolytic therapy needs to take into
consideration the potential bleeding risk for the individual patient, as
well as the potential benefits from early clot lysis. For patients with DVT
who will be treated with thrombolytic therapy, the decision about
whether to use catheter-directed thrombolysis or systemic thrombol-
ysis is addressed in Recommendation 8. Additional research is
necessary to facilitate the identification of which patients with DVT
would benefit most from thrombolytic therapy.
Recommendation 6
For patients with PE and hemodynamic compromise, the ASH
guideline panel recommends using thrombolytic therapy fol-
lowed by anticoagulation over anticoagulation alone (strong
recommendation despite low certainty in the evidence of
effects ÅÅ○○).
Remarks: Strong recommendations based on low certainty in
the evidence of effects are exceptional. In this case, the high
mortality of patients with PE and hemodynamic compromise, as
well as the potential lifesaving effect of thrombolytics, war-
ranted a strong recommendation. This exception is in accor-
dance with the exceptional circumstances that allow strong
recommendations based on low-certainty evidence in the
GRADE ASH rules.
Summary of the evidence
We identified 29 systematic reviews151-179 and 26 RCTs (n 5
2787).130,180-204 Trials included individuals with an objectively
confirmed symptomatic PE. Most trials included patients without
hemodynamic compromise but with ultrasonography or biomarkers
compatible with right ventricular dysfunction (submassive PE).
Participants were randomized to thrombolytic therapy in addition
to anticoagulation or to anticoagulation alone. Thrombolytics
were systemically infused in all of the trials with the exception of 1,190




The use of thrombolytics for patients with PE and hemodynamic
compromise may reduce mortality (RR, 0.61; 95% CI, 0.40-0.94;
ARR, 58 fewer per 1000 patients; 95% CI, 9 fewer to 90 fewer;
low-certainty evidence).
Additionally, thrombolytic therapy might reduce the risk of sub-
sequent PE (RR, 0.56; 95% CI, 0.35-0.91; ARR, 7 fewer per 1000
patients; 95% CI, 10 fewer to 2 fewer; very-low-certainty
evidence) and DVT (RR, 0.92; 95% CI, 0.14-6.03; ARR, 1 fewer
per 1000 patients; 95% CI, 8 fewer to 46 more; very-low-
certainty evidence).
Harms and burden
The use of thrombolytics for patients with VTE (PE or DVT) was
associated with an increase in the risk of major bleeding (RR,
1.89; 95% CI, 1.46-2.46; ARR, 31 more per 1000 patients; 95%
CI, 16 more to 51 more; high-certainty evidence) and intracra-
nial bleeding (RR, 3.17; 95% CI, 1.19-8.41; ARR, 7 more per
1000 patients; 95% CI, 1 more to 21 more; moderate-certainty
evidence).
We tested whether the risk of major bleeding varied with the
different routes of administration (ie, systemic vs locoregional vs
catheter directed) and found that the effects were similar,
regardless of the strategy used (RR for systemic infusion, 1.74;
RR for catheter-directed infusion, 3.77; RR for locoregional
infusion, 4.14).
Certainty in the evidence of effects
The certainty in the evidence was judged as low for mortality
because of indirectness and imprecision. The trials identified
primarily included patients without hemodynamic compromise,
and the panel judged that thrombolytic effect may be different in
such patients. Also, the number of patients studied was relatively
small compared with the optimal information size, and the CIs
around the absolute effect likely crossed the thresholds that
patients would consider important. The same was true for the
outcomes PE and DVT, but in addition to indirectness and
imprecision, the panel also rated this down by risk of bias, given
that none of the included trials was blinded.
Finally, the certainty in the evidence for major bleeding was judged
as high.
Other EtD criteria and considerations
The panel considered that most informed patients would place
more value in avoiding death than in the risk of bleeding associated
with thrombolysis. Also, although no direct evidence was identified,
in the context of hemodynamically unstable patients, the potential
benefit of thrombolytic therapy on survival would probably result in
the intervention being cost-effective. Finally, the panel considered
that thrombolysis is acceptable and feasible to implement in most
scenarios.
Conclusions and implementation considerations
Approximately 3% to 5% of patients with an acute PE present
with hemodynamic compromise, defined as a systolic blood pressure
,90 mm Hg or a decrease in systolic blood pressure $40 mm Hg
from baseline.205,206 These patients are at a significantly greater risk
for mortality, as high as 50% by 90 days,205 compared with patients
with acute PE who do not present with hemodynamic compromise.
As documented above, although thrombolytic therapy may reduce
mortality for patients with PE and hemodynamic compromise, it is
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also associated with an increased risk for major bleeding and
intracranial bleeding. Nevertheless, because of the high risk of
mortality in this small subset of patients with PE, the ASH guideline
panel provided a strong recommendation in favor of the use of
thrombolytic therapy (the decision as to whether this should be
systemic or catheter-directed thrombolysis is addressed in
Recommendation 9). Implementation of this recommendation
depends on the ability to rapidly evaluate patients, confirm the
diagnosis of PE and associated hemodynamic compromise, and
initiate appropriate therapy. Multidisciplinary PE response teams
have recently been implemented at several institutions to expedite
rapid assessment and decision-making for these patients207,208;
however, there has not been a demonstrated improvement in
mortality with this approach.208,209 Additional research with
clinical outcomes is needed to confirm the role of thrombo-
lytic therapy for patients with PE and hemodynamic compro-
mise, including the optimal strategy for administration of the
thrombolytic.
Recommendation 7
For patients with PE with echocardiography and/or biomarkers
compatible with right ventricular dysfunction but without he-
modynamic compromise (submassive PE), the ASH guideline
panel suggests anticoagulation alone over the routine use of
thrombolysis in addition to anticoagulation (conditional rec-
ommendation based on low certainty in the evidence of effects
ÅÅ○○).
Remarks: Thrombolysis is reasonable to consider for younger
patients with submassive PE at low risk for bleeding. Patients
with submassive PE should be monitored closely for the de-
velopment of hemodynamic compromise.
Summary of the evidence
We identified 29 systematic reviews151-179 and 26 RCTs (n 5
2787).130,180-204 Trials included individuals with an objectively
confirmed symptomatic PE. Most trials included patients without
hemodynamic compromise but with ultrasonography or bio-
markers compatible with right ventricular dysfunction (submas-
sive PE). Participants were randomized to thrombolytic therapy
in addition to anticoagulation or to anticoagulation alone.
Thrombolytics were systemically infused in all of the trials with
the exception of 1,190 in which it was administered through




The use of thrombolytics for patients with PE and hemodynamic
compromise may reduce mortality (RR, 0.61; 95% CI, 0.40-0.94;
ARR, 58 fewer per 1000 patients; 95% CI, 9 fewer to 90 fewer;
low-certainty evidence).
Additionally, thrombolytic therapy might reduce the risk of sub-
sequent PE (RR, 0.56; 95% CI, 0.35-0.91; ARR, 7 fewer per 1000
patients; 95% CI, 10 fewer to 2 fewer; very-low-certainty evidence)
and DVT (RR, 0.92; 95% CI, 0.14-6.03; ARR, 1 fewer per 1000
patients; 95% CI, 8 fewer to 46 more; very-low-certainty evidence).
Harms and burden
The use of thrombolytics for patients with VTE (PE or DVT) was
associated with an increased risk for major bleeding (RR, 1.89;
95% CI, 1.46-2.46; ARR, 31 more per 1000 patients; 95% CI,
16 more to 51 more; high-certainty evidence) and intracranial
bleeding (RR, 3.17; 95% CI, 1.19-8.41; ARR, 7 more per 1000
patients; 95% CI, 1 more to 21 more; moderate-certainty
evidence).
We tested whether the risk of major bleeding varied with the
different routes of administration (ie, systemic vs locoregional vs
catheter directed) and found that the effects were similar,
regardless of the strategy used (RR for systemic infusion, 1.74;
RR for catheter-directed infusion, 3.77; RR for locoregional
infusion, 4.14).
Certainty in the evidence of effects
The certainty in the evidence was judged as low for mortality
because of indirectness and imprecision. The trials identified
primarily included patients without hemodynamic compromise,
and the panel judged that thrombolytic effect may be different in
such patients. Also, the number of patients studied was
relatively small compared with the optimal information size,
and the CIs around the absolute effect likely crossed the
thresholds that patients would consider important. The same
was true for the outcomes PE and DVT, but in addition to
indirectness and imprecision, the panel also rated these
outcomes down by risk of bias, given that none of the included
trials was blinded.
Finally, the certainty in the evidence for major bleedingwas judged as high.
Other EtD criteria and considerations
We considered that most informed patients would place
more value in avoiding death than in the risk of bleeding
associated with the intervention. Finally, we considered that
thrombolysis is acceptable and feasible to implement in most
scenarios.
Conclusions and implementation considerations
Patients with acute PE who do not have evidence of hemodynamic
compromise, defined as a systolic blood pressure ,90 mm Hg
or a decrease in systolic blood pressure $40 mm Hg from
baseline, but who do have evidence of right ventricular strain
by echocardiography or elevated cardiac biomarker levels (eg,
elevated troponins or natriuretic peptides), have a higher mortal-
ity than do patients without these findings.210,211 However, the
mortality risk is much less than for those patients with hemodynamic
compromise. Consequently, because of this lower risk for mortality
and the low certainty in the evidence of effects, the ASH guideline
panel has provided a conditional recommendation against the
routine use of thrombolytic therapy in these patients. This decision
needs to be individualized, however, because some patients
with acute PE may be assessed as being at higher risk for
mortality (eg, patients with comorbid cardiopulmonary condi-
tions) than others. Implementation of this recommendation
depends on the ability to rapidly evaluate patients and initiate
appropriate therapy. Additional research should target whether
certain subsets of patients with acute PE and evidence of right
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ventricular strain, but without hemodynamic compromise, would
benefit from thrombolytic therapy.
Recommendation 8
For patients with extensive DVT in whom thrombolysis is con-
sidered appropriate, the ASH guideline panel suggests using
catheter-directed thrombolysis over systemic thrombolysis
(conditional recommendation based on very low certainty in the
evidence of effects Å○○○).
Remarks: Given the very-low-certainty evidence (uncertainty
regarding the benefits and harms of catheter-directed thrombol-
ysis compared with systemic thrombolysis), the panel followed the
GRADE rules and issued a conditional recommendation. How-
ever, 4 panel members believed that the recommendation should
have been graded as strong based on the uncertain benefit of
catheter-directed thrombolysis over systemic thrombolysis and
the certain and serious bleeding risks associated with systemic
thrombolysis.
Summary of the evidence
We identified 3 systematic reviews119,212,213 and 5 controlled trials
(n 5 427).142,214-217 Trials included individuals with objectively
confirmed symptomatic proximal DVT. Participants were random-
ized to directed therapy or systemic thrombolytic therapy. In 4
trials,214-217 thrombolysis was catheter directed, whereas in 1,142 it




For patients with DVT, catheter-directed thrombolysis might
reduce the risk of PE (RR, 0.26; 95% CI, 0.05-1.43; ARR, 11
fewer per 1000 patients; 95% CI, 14 fewer to 6 more; very-low-
certainty evidence) and of major bleeding (RR, 0.35; 95% CI,
0.12-1.06; ARR, 29 fewer per 1000 patients; 95% CI, 40 fewer
to 3 more; very-low-certainty evidence). However, there is consider-
able uncertainty regarding the comparative effectiveness of catheter-
directed thrombolysis vs systemic thrombolysis given that CIs include
evidence for benefit and harm.
Harms and burden
Catheter-directed thrombolysis might increase the risk of PTS (RR,
2.59; 95% CI, 1.42-4.74; ARR, 223 more per 1000 patients; 95% CI,
76 more to 369 more; very-low-certainty evidence). However, there is
considerable uncertainty given the wide CIs surrounding the effect.
Certainty in the evidence of effects
The certainty in the evidence was judged as very low for all of the
relevant outcomes. None of the trials were blinded, increasing
the possibility of bias. However, the most serious limitation of the
evidence supporting this decision was the small number of patients
studied. The number of events in the trials was very small, which led
to wide CIs around the absolute estimates. Additionally, the
certainty in the evidence was rated down because of indirectness
in the outcome of PTS, because the only trial that informed this
outcome used locoregional thrombolysis instead of catheter-
directed thrombolysis.
Other EtD criteria and considerations
Given the small body of evidence supporting this decision, there is
likely to be variability in what informed patients may choose.
Also, catheter-directed thrombolysis is an expensive procedure, and
its implementation would probably result in an increment of direct
costs. In the absence of certainty of its effects, it is not possible to
reliably estimate its cost-effectiveness.
Finally, catheter-directed thrombolysis is not universally available,
given that specialized laboratory support and trained personnel are
required, and it might not be acceptable for some stakeholders.
It is important to note that systemic thrombolysis is not offered as an
option for DVT management in the United States. Therefore, this
recommendation does not fully apply to the US setting, but the panel
considered the knowledge gap underlying this practice important
to note.
Conclusions and implementation considerations
The ASH guideline panel suggested that most patients with proximal
DVT do not need thrombolytic therapy in addition to anticoagulation
in Recommendation 5. However, for those patients with DVT for
whom thrombolytic therapy is considered appropriate, the ASH
guideline panel provided a conditional recommendation in favor of
catheter-directed thrombolysis over systemic thrombolysis,
based on the very low certainty in the level of evidence. As
noted above, 4 panel members believed that this should be
a strong recommendation because systemic thrombolysis is not
considered appropriate therapy in the United States. Regardless
of the strength of the recommendation, implementation is
contingent upon the local availability of appropriate technical
expertise and infrastructure. Future research studies need to
focus on the patient populations with DVT in whom thrombolytic
therapy is considered most appropriate, to identify the optimal
approach for administration of thrombolytic therapy.
Recommendation 9
For patients with PE in whom thrombolysis is considered
appropriate, the ASH guideline panel suggests using sys-
temic thrombolysis over catheter-directed thrombolysis
(conditional recommendation based on very low certainty in
the evidence of effects Å○○○).
Remarks: In centers with the appropriate infrastructure, clini-
cal staff, and procedural experience, catheter-directed throm-
bolysis may be an alternative to systemic thrombolysis,
especially for patients with an intermediate risk for bleeding,
because the total dose of thrombolytic agents is lower when de-
livered by catheter. In arriving at this recommendation, the panel
acknowledged that the reduced dose of thrombolytic drug used
for catheter-directed thrombolysis might confer a safety advan-
tage. However, estimates of the bleeding rate associated with
catheter-directed thrombolysis are very imprecise because of the
paucity of quality studies and the diversity of methods used. The
single published randomized trial that evaluated efficacy was small
and did not demonstrate clinical outcome improvements beyond
cardiac hemodynamic parameters. Hence, there remains sub-
stantial uncertainty surrounding the actual safety and efficacy of
catheter-directed thrombolysis. In contrast, estimates of the safety
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and efficacy of systemic thrombolysis are more confident, having
been derived from many randomized trials comprising a much
larger number of patients.
Summary of the evidence
We identified 1 systematic review,218 1 relevant controlled trial (n5
52),219 and 3 relevant observational studies (matched population5
7502).220-222 All of the studies included individuals with an
objectively confirmed PE and compared catheter-directed throm-
bolysis with systemic thrombolysis. The EtD framework is shown
online at: https://guidelines.gradepro.org/profile/A7BFDBC4-6A3F-
D87D-928A-7ADA50ADED1A.
Benefits, harms, and burden
There is considerable uncertainty regarding the comparative effect
of systemic thrombolysis and catheter-directed thrombolysis.
Based on 1 very small trial and 3 observational studies, the use of
catheter-directed thrombolysis might reduce mortality (RCT esti-
mate: RR, 0.06; 95% CI, 0-0.96; ARR, 157 fewer per 1000
patients; 95% CI, 7 fewer to 167 fewer; very-low-certainty
evidence; observational studies estimate: odds ratio [OR], 0.59;
95% CI, 0.33-1.04; ARR during hospitalization, 48 fewer per 1000
patients; 95% CI, 81 fewer to 4 more; very low certainty). Also,
catheter-directed thrombolysis might reduce major bleeding (RCT
estimate: RR, 0.69; 95% CI, 0.21-2.27; ARR, 24 fewer per 1000
patients; 95%CI, 62 fewer to 99 more; very-low-certainty evidence;
observational studies estimate: OR, 0.87; 95%CI, 0.7-1.09; ARR, 7
fewer per 1000 patients; 95% CI, 16 fewer to 5 more; very low
certainty).
PE recurrence and DVT were not reported in any of the identified
studies.
Certainty in the evidence of effects
The certainty in the evidence was judged as very low for mortality
and major bleeding because of the risk of bias and imprecision.
The only randomized trial was not blinded, and the randomization
process was not adequately described. The observational study
did adjust for baseline characteristics using propensity scores,
but observational studies have a residual selection bias due
to unadjusted or unmeasured differences in the groups under
comparison.
The other main limitation of the evidence supporting this decision
was imprecision of the estimates. In the randomized trial, only 54
patients were studied, yielding a very wide CI. Although the
observational studies did include more patients and events, the CIs
around the absolute estimates were also wide and probably
crossed the thresholds that patients would consider important.
Other EtD criteria and considerations
Given the small body of evidence supporting this decision, there is
likely to be variability in what informed patients may choose.
We did not identify relevant economic evaluations, although
catheter-directed thrombolysis is an expensive procedure, and
its implementation probably would result in an increment of
direct costs.
Because catheter-directed thrombolysis requires a specialized
laboratory and trained personnel, it is not universally available. Also,
given its costs and the uncertainty regarding its effects, it might not
be acceptable for some stakeholders.
Conclusions and implementation considerations
Thrombolytic therapy can be an appropriate intervention in selected
patients with PE, as described in Recommendations 6 and 7, and
can be administered systemically or using a catheter-directed
approach. Based on the very low level of certainty in the
evidence, as outlined above, the ASH guideline panel has
provided a conditional recommendation favoring systemic
thrombolysis over catheter-directed thrombolysis for those
patients with PE in whom thrombolysis is considered clinically
appropriate. The panel did recognize the potential safety
advantage of using a catheter-directed approach, but the
imprecision of the data limited any conclusions that would favor
this approach. Future research studies need to be conducted in
the appropriate patient populations and designed to answer
these questions surrounding optimal administration of thrombo-
lytic therapy for patients with PE.
Recommendations 10 and 11
For patients with proximal DVT and significant preexisting
cardiopulmonary disease, as well as for patients with PE and
hemodynamic compromise, the ASH guideline panel suggests
anticoagulation alone rather than anticoagulation plus insertion
of an IVC filter (conditional recommendations based on low
certainty in the evidence of effects ÅÅ○○).
Remarks: These recommendations apply to patients who are
eligible to receive anticoagulation. For patients with a contra-
indication to anticoagulation, insertion of a retrievable IVC filter
may be indicated, with retrieval as soon as the patient is able to
receive anticoagulation.
Summary of the evidence
We identified 7 systematic reviews223-229 and 2 randomized
trials230,231 (n 5 799). The PREPIC230 trial included 400 patients
with proximal DVT with or without concomitant PE. Participants
were randomized to insertion of a nonretrievable IVC filter in
addition to anticoagulation or to anticoagulation alone. Patients
were followed for 2 years. The PREPIC 2 trial231 included 399
patients with PE and acute deep or superficial vein thrombosis.
Participants were randomized to insertion of a retrievable IVC filter
in addition to anticoagulation or to anticoagulation alone. Follow-
up was for 6 months. The majority of patients included in the
PREPIC trials did not have significant preexisting cardiopulmonary
disease, and no patient had PE with hemodynamic failure. The EtD





A nonsignificant reduction in the risk of PE with IVC filter was
observed (RR, 0.54; 95% CI, 0.22-1.33; ARR, 2 fewer per 1000
patients; 95% CI, 4 fewer to 2 more; low-certainty evidence). Using
the baseline risk of PE observed in a cohort of 4036 patients
with chronic obstructive pulmonary disease and VTE,232 we
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estimated that the use of an IVC filter may lead to 13 fewer
PEs (95% CI, 23 fewer to 10 more; low-certainty evidence).
Harms and burden
We observed a nonsignificant mortality increase for patients
randomized to receive IVC filters (RR, 1.12; 95% CI, 0.83-1.60;
ARR, 9 more per 1000 patients; 95% CI, 10 fewer to 36 more;
low-certainty evidence). Using the mortality observed in a cohort
of 4036 patients with chronic obstructive pulmonary disease
and VTE as baseline risk,232 we estimated that the use of IVC
filters for patients with significant preexisting cardiopulmonary
disease may lead to 16 more deaths per 1000 (95% CI, 19
fewer to 66 more; low-certainty evidence). Also, using the
baseline risk of mortality observed for patients with PE and
systolic blood pressure ,90 mmHg in the RIETE registry (n 5
6599),233 we estimated that the use of an IVC filter for patients
with PE and hemodynamic compromise may lead to 22 more
deaths per 1000 (95% CI, 26 fewer to 90 more; low-certainty
evidence).
Additionally, we observed a nonsignificant increase in the incidence
of subsequent DVT in the group randomized to IVC filters (RR, 1.64;
95% CI, 0.93-2.90; ARR, 3 more per 1000 patients; 95% CI, 0 to
10 more; low-certainty evidence).
Finally, IVC filter insertion was associated with local and mechanical
complications. In the PREPIC 2 trial,231 among the 193 patients
who received filters, 5 (2.6%) experienced access site hematoma, 3
(1.6%) experienced filter thrombosis, and 11 (5.7%) experienced
retrieval failure for mechanical reasons.
Certainty in the evidence of effects
The certainty in the evidence was judged low for all of the relevant
outcomes. One of the limitations of the available evidence was that
the populations included in the PREPIC trials were different from
our populations of interest. Specifically, the risk of death and PE
observed in the trials probably underestimated the real risk of
patients with significant preexisting cardiopulmonary disease and
with PE and hemodynamic failure. The panel took this factor into
consideration by using baseline risks observed in the relevant
populations in observational studies and by rating down by
indirectness.
Additionally, the panel rated down the certainty in the evidence
by imprecision, given that the CI around the absolute estimates
likely crossed the thresholds that patients would consider
important.
Other EtD criteria and considerations
The panel considered that the balance between the risks of PE vs
death and subsequent DVT episodes was critical for patients,
although there likely is important variation in how individual patients
may value the different outcomes.
The panel did not find economic evaluations assessing the cost-
effectiveness of IVC filters; however, the panel considered that the
costs associated with the insertion and removal of IVC filters are at
least moderate.
Conclusions and implementation considerations
IVC filters were designed almost 50 years ago to trap blood clots
originating from the veins in the pelvis and lower extremities,
preventing them from occluding the pulmonary vasculature while
maintaining caval patency.234 Recommendations 10 and 11
consider patients who would be considered most likely to
benefit from this type of device, specifically those with significant
preexisting cardiopulmonary disease and those with hemody-
namic compromise related to preexisting PE. If these patients
can be safely treated with anticoagulant therapy, however, the
ASH guideline panel conditionally recommends against the use
of IVC filters, based on the low certainty in the evidence of their
effects. Importantly, these recommendations are not intended to
apply to patients with VTE who have a contraindication to
anticoagulant therapy, in whom placement of an IVC filter may be
an important alternative. If an IVC filter is going to be deployed,
the panel recommends use of a retrievable filter, with removal
once the patient is able to be safely treated with anticoagulant
therapy.
Primary treatment
Recommendations 12, 13, and 14 address the question of the
appropriate duration of time that should be used for primary
treatment of the acute event, as defined in Figure 2. The individual
recommendations reference 3 patient populations: those with
VTE provoked by transient risk factors (Recommendation 12),
those with VTE provoked by chronic (persistent) risk factors
(Recommendation 13), and those with VTE not associated with
any provoking risk factors (ie, unprovoked VTE; Recommendation
14). Common examples of major and minor transient risk factors
and chronic risk factors for VTE are provided in Table 3.
Several studies have demonstrated that primary treatment
should continue for a minimum of 3 to 6 months for all patients
with VTE.235,236 The recommendations in this section address
whether the 3 patient populations described above would
benefit from a longer period for primary treatment of the acute
thromboembolic event. Of note, these recommendations do
not address whether patients should continue antithrombotic
therapy indefinitely to prevent recurrent events, referred to as
secondary prevention in Figure 2, which is covered in the
section on secondary prevention below.
Recommendations 12, 13, and 14
For primary treatment of patients with DVT and/or PE, whether
provoked by a transient risk factor (Recommendation 12) or
a chronic risk factor (Recommendation 13) or unprovoked
(Recommendation 14), the ASH guideline panel suggests
using a shorter course of anticoagulation for primary treat-
ment (3-6 months) over a longer course of anticoagulation
for primary treatment (6-12 months) (conditional recom-
mendations based on moderate certainty in the evidence of
effects ÅÅÅ○).
Remarks: These recommendations are intended to address
the duration of primary anticoagulant treatment for all patients
with DVT and/or PE, defined as the minimal length of time for
treatment of the initial VTE (Figure 2). Most patients with DVT
and/or PE provoked by temporary risk factors will discontinue
anticoagulant therapy after completion of the primary treat-
ment. In contrast, many patients with DVT and/or PE provoked
by chronic risk factors, as well as patients with unprovoked DVT
and/or PE, may continue anticoagulant therapy indefinitely for
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secondary prevention after completion of the primary treatment
(Figure 2). However, if patients and clinicians decide to stop
anticoagulation after primary treatment, the ASH guideline
panel suggests against using a longer course of primary anti-
coagulant therapy (6-12 months). For selected patients with
a chronic risk factor for which some improvement is expected
over time (eg, improved mobility with rehabilitation), a longer
course of anticoagulation for the primary treatment phase
(eg, 6-12 months) could be justified. Recommendations
15 through 22 address decisions concerning which patients
should indefinitely continue anticoagulant therapy for second-
ary prevention and which therapeutic options should be con-
sidered.
Recommendation 12: primary treatment for patients
with DVT and/or PE provoked by a transient
risk factor
Summary of the evidence. We identified 19 systematic
reviews239-257 and 10 RCTs (n 5 2857).258-267 One set of trials
included adults with objectively confirmed DVT and/or PE at the
time of diagnosis, who were randomized to a shorter course (3-6
months) or a longer course (6-12 months) of anticoagulant therapy
for primary treatment. A second set of trials included adults with
objectively confirmed DVT and/or PE who had completed treatment
with anticoagulants for 3 to 6 months without recurrence and who
were then randomized to receive placebo or continue for
$6 months of additional treatment. The longer course of therapy
varied from 6 months to 24 months.262 Patients were continuously
followed up until the end of the longer course of anticoagulation.
The outcomes were measured in both groups at the end of the
follow-up. For baseline risks of VTE, we used a meta-analysis of 10
cohort studies and 5 randomized trials268 that reported a VTE
recurrence rate of 4.2 per 100 patient-years for patients with
a transient risk factor. Assuming that 45% of the VTE events are
PEs and 55% are DVTs,269 we estimated annualized risks of PE
recurrence of 1.89 and of DVT recurrence of 2.31 per 100 patient-
years for patients with a nonsurgical transient risk factor. For the
baseline risk of major bleeding, we used a meta-analysis of 13
prospective cohort studies and 56 randomized trials98 in VTE
patients showing a 2.1% risk for major bleeding during a 6-month
treatment with anticoagulants. We estimated an annualized risk for
major bleeding of 2.1%, assuming a risk for major bleeding close to
0 after anticoagulant discontinuation. The EtD framework is shown
online at: https://guidelines.gradepro.org/profile/68333EE3-3DBA-
5D42-A7AC-B4A3258F08E0.
Benefits. The meta-analysis showed that, compared with
a shorter course of anticoagulation, treating patients with a longer
course of anticoagulation reduced the risk of DVT (RR, 0.50; 95%
CI, 0.27-0.95; ARR, 59 fewer per 1000 patients; 95% CI, 86 fewer
to 6 fewer; high-certainty evidence). In a low-risk population,268
a longer course of anticoagulation also reduced the risk of DVT
(ARR, 18 fewer per 1000 patients; 95% CI, 21 fewer to 14 fewer).
A longer course of anticoagulation also showed a potential
reduction in the risk of PE in the study population, without statistical
significance (RR, 0.66; 95% CI, 0.29-1.51; ARR, 17 fewer per
1000 patients; 95% CI, 35 fewer to 25 more; moderate-certainty
evidence) and likely a small reduction in a low-risk population268
(ARR, 6 fewer per 1000 patients; 95% CI, 13 fewer to 10 more;
Recommendations 12-14 Recommendations 18-22
Recommendations 15-17
Primary Treatment Secondary Prevention
3 to 6 months, or longer? Stop after primary treatment




Figure 2. Relationships of Recommendations 12 to 22 with primary
treatment and secondary prevention phases of VTE treatment. Recommenda-
tions 12 to 14 address the duration of the primary treatment phase of therapy.
Recommendations 15 to 17 address strategies to decide whether to discontinue
anticoagulant therapy or continue with secondary prevention. Recommendations 18
to 22 address which patients should receive secondary prevention and with what
antithrombotic therapies.
Table 3. Risk factors and venous thromboembolism
Transient risk factors (risk factors that resolve after they have provoked VTE)*
Major transient risk factors (occur within 3 mo of VTE diagnosis); examples
include:
Surgery with general anesthesia for $30 min
Confined to bed in hospital for $3 d with an acute illness (“bathroom privileges” only)
Cesarean section
Minor transient risk factors (occur within 2 mo of VTE diagnosis); examples
include:
Surgery with general anesthesia for ,30 min
Admission to hospital for ,3 d with an acute illness
Estrogen therapy (eg, oral contraceptives, hormone replacement therapy)
Pregnancy and puerperium
Confined to bed out of hospital for $3 d with an acute illness
Leg injury associated with decreased mobility for $3 d
Chronic (persistent) risk factors (risk factors that persist after the development
of VTE)†
Active cancer (eg, ongoing chemotherapy; recurrent or progressive disease)
Inflammatory bowel disease
Autoimmune disorders (eg, antiphospholipid syndrome, rheumatoid arthritis)
Chronic infections
Chronic immobility (eg, spinal cord injury)
Patients may present with .1 transient risk factor or a combination of transient and
chronic risk factors. Nonenvironmental risk factors for VTE include hereditary thrombophilia,
older age, and male sex. These variables typically exhibit a low relative risk for VTE but may
be useful in combination with acquired risk factors when considering an individual patient’s
risk for recurrence. Other acquired variables that confer a very weak risk for recurrence
(OR , 2), such as obesity, varicose veins, or laparoscopic surgery, are not considered
significant risk factors individually, but they may have an additive effect when combined with
other risk factors listed above. Adapted from Kearon et al237 and Konstantinides et al238
with permission.
*For patients with VTE and a major transient risk factor .3 months prior to the VTE or
a single minor transient risk factor .2 months prior to the VTE, clinical judgment is
essential when considering the contribution of this variable to the initial VTE and the risk of
recurrence.
†Chronic risk factors may fluctuate over time (eg, curative treatment of cancer or clinical
waxing and waning of an autoimmune disorder), which may impact the relative risk of
recurrent VTE. Active cancer is addressed in a future guideline document from ASH and is
not considered in this article.
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moderate-certainty evidence). Using a DOAC for the longer course
of anticoagulation reduced the risk of DVT in the study population
(RR, 0.21; 95% CI, 0.11-0.41; ARR, 62 fewer per 1000 patients;
95% CI, 70 fewer to 46 fewer; moderate-certainty evidence), as
well as in a low-risk population268 (ARR, 18 fewer per 1000
patients; 95% CI, 21 fewer to 14 fewer; high-certainty evidence). A
longer course of a DOAC also reduced the risk of PE for the study
population (RR, 0.13; 95% CI, 0.03-0.58; ARR, 21 fewer per 1000
patients; 95% CI, 24 fewer to 10 fewer), as well as for a low-risk
population (ARR, 16 fewer per 1000 patients, 95% CI, 18 fewer to
8 fewer; moderate-certainty evidence).
Using a VKA or LMWH for the longer course of anticoagulation
resulted in a reduction in the risk of DVT without statistical
significance for the study population (RR, 0.60; 95% CI, 0.32-1.11;
ARR, 64 fewer per 1000 patients; 95% CI, 109 fewer to 18 more),
as well as for a low-risk population (ARR, 9 fewer per 1000 patients;
95% CI, 16 fewer to 3 more; moderate-certainty evidence). There
was no significant impact on the risk of PE in the study population
(RR, 0.84; 95% CI, 0.43- 1.66; ARR, 13 fewer per 1000 patients;
95% CI, 47 fewer to 55 more) or for a low-risk population268 (ARR,
3 fewer per 1000 patients; 95% CI, 11 fewer to 12 more;
moderate-certainty evidence).
Harms and burden. Our analysis showed a potential increase
in mortality when using a longer course of anticoagulation than
with a shorter course of anticoagulation, without statistical
significance (RR, 1.38; 95% CI, 0.85-2.23; ARR, 7 more per
1000 patients; 95% CI, 3 fewer to 22 more; moderate-certainty
evidence).
The use of a longer course of anticoagulation may increase the
risk of major bleeding (RR, 1.46; 95% CI, 0.78-2.73; ARR, 6
more per 1000 patients; 95% CI, 3 fewer to 22 more; moderate-
certainty evidence). In populations with a low risk for bleeding,98
the use of a longer course, instead of a shorter course, of
anticoagulation may lead to an increase of 10 more bleeding events
per 1000 patients (95% CI, 5 fewer to 36 more; moderate-certainty
evidence).
Certainty in the evidence of effects. The certainty in the
evidence was judged moderate for mortality, PE, and major bleeding
because of imprecision, given that the CI around the absolute
estimates likely crossed the thresholds that patients would consider
important. Therefore, it was not possible to completely rule out
a small difference between the alternatives on such outcomes. For
DVT, the certainty in the evidence was judged high. In the subgroup
analysis performed, there are 2 cases in which the quality of the
evidence differed from the original analysis. Both of these are for
DVT outcome when using a VKA, LMWH, or a DOAC. The
certainties of the evidence were judged moderate because of
imprecision.
Other EtD criteria and considerations. We considered that
avoidance of PE, DVT, and bleeding was critical for patients.
However, there may be important variability in how individual
patients value the risk of thrombosis vs the risk of bleeding. We did
not identify direct evidence of a cost-effectiveness comparison for
nonsurgical-provoked DVT/PE. Four Markov model analyses of
cost-effectiveness for a longer course of antithrombotic therapy vs
a shorter course of antithrombotic therapy for VTE treatment
were identified. Three analyses showed that the longer course was
cost-effective compared with the shorter course of antithrombotic
therapy,112,270, 271 whereas 1 analysis suggested that a longer course
of anticoagulation with warfarin was cost-effective in younger patients
and 3 months of anticoagulation was preferred in elderly patients (80-
year-old subgroup).272
The panel considered that a longer course of treatment was
probably acceptable and feasible. Observational studies suggested
a higher level of patient satisfaction with a DOAC and a lower
treatment burden compared with LMWH or a VKA.273
Conclusions and implementation considerations. The risk
for recurrent VTE is low following completion of a course of
anticoagulant therapy as primary treatment for patients who sustain
a thromboembolism in the setting of a transient risk factor.268
Transient risk factors may be surgical or nonsurgical events (eg,
hospitalization for an acute illness, estrogen therapy, or pregnancy),
and, by definition, they resolve or can be discontinued (Table 3). The
risk for a recurrent VTE is lower following a thromboembolism
provoked by a surgical procedure or trauma compared with
a nonsurgical risk factor, but the risk is low for both groups
overall.268 A longer course of therapeutic anticoagulation for the
primary treatment phase may decrease the risk of recurrent VTE
while on treatment, but this is offset by an increased risk for
bleeding complications. In addition, several of the studies identified
above observed that any benefit associated with a longer finite
course of therapy is lost after anticoagulation is discontinued.257,261
The ASH guideline panel provided a conditional recommendation
supporting a shorter course (3-6 months) of therapy over a longer
duration (6-12 months) for this phase of treatment as a result of the
moderate certainty in the evidence of effects. After completion of
the primary treatment phase, anticoagulant therapy is typically
discontinued for patients with VTE provoked by transient risk
factors, and secondary prevention does not need to be considered
(Figure 2).
It should be noted that this recommendation is based primarily on
data obtained from trials using VKA as the anticoagulant therapy. It
is possible that newer studies using DOACs could alter the
balance of benefits and harms associated with a longer course of
therapy.
Recommendation 13: primary treatment for patients
with DVT and/or PE provoked by a chronic risk factor
Summary of the evidence. We identified 19 systematic
reviews239-257 and 10 RCTs258-267 (n 5 2857). One set of trials
included adults with objectively confirmed DVT and/or PE at the
time of diagnosis, who were randomized to a shorter course (3-6
months) or a longer course (6-12 months) of anticoagulant therapy.
A second set of trials included adults with objectively confirmed
DVT and/or PE who had been treated with anticoagulants for 3 to
6 months without recurrence; they were randomized to receive
placebo or continue treatment for $6 more months. The longer
course of therapy varied from 6 months to 24 months.262 Patients
were followed after the end of the extended anticoagulation
treatment. The outcomes were measured in both groups at the
end of the follow-up period. For baseline risks of VTE, we used
a multicenter prospective cohort study274 that included 646
participants reporting a VTE recurrence rate of 9.7% per patient-
year for patients with a chronic risk factor. Assuming that 45% of the
VTE events are PEs and 55% are DVTs,269 we estimated annualized
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risks of recurrent PE of 4.4 and of recurrent DVT of 5.3 per
100 patient-years for patients with a chronic risk factor. For the
baseline risk of major bleeding, we used a meta-analysis of 13
prospective cohort studies and 56 randomized trials98 in VTE
patients showing a 2.1% risk for major bleeding during a 6-month
treatment with anticoagulants. We estimated an annualized risk for
major bleeding of 2.1%, assuming a risk for major bleeding close to
0 after anticoagulant discontinuation. The EtD framework is shown
online at: https://guidelines.gradepro.org/profile/55B22415-DEB8-
D1B7-9512-224BE01DCC76.
Benefits. The meta-analysis showed that, compared with
a shorter course of anticoagulation, treating patients with
a longer course of anticoagulation reduced the risk of DVT
(RR, 0.50; 95% CI, 0.27-0.95; ARR, 59 fewer per 1000
patients; 95% CI, 86 fewer to 6 fewer; high-certainty evidence).
In a low-risk population,274 a longer course of anticoagulant
therapy reduced the risk of DVT as well (ARR, 27 fewer per
1000 patients; 95% CI, 39 fewer to 3 fewer). A longer course of
anticoagulation also showed a potential reduction in the risk of
PE in the study population, without statistical significance (RR,
0.66; 95% CI, 0.29-1.51; ARR, 17 fewer per 1000 patients;
95% CI, 35 fewer to 25 more; moderate-certainty evidence),
and likely a small reduction in the low-risk population274 (ARR,
15 fewer per 1000 patients; 95% CI, 31 fewer to 22 more;
moderate-certainty evidence). When using a DOAC for a longer
course of anticoagulation, the risk of DVT was reduced in the
study population (RR, 0.21; 95% CI, 0.11-0.41; ARR, 62 fewer
per 1000 patients; 95% CI, 70 fewer to 46 fewer; moderate-
certainty evidence), as well as in the low-risk population274
(ARR, 42 fewer per 1000 patients; 95% CI, 47 fewer to 31
fewer; moderate-certainty evidence). A longer course of
therapy with a DOAC also reduced the risk of PE (RR, 0.13;
95% CI, 0.03-0.58; ARR, 21 fewer per 1000 patients; 95% CI,
24 fewer to 10 fewer for study population; ARR, 38 fewer per
1000 patients; 95% CI, 42 fewer to 18 fewer for low-risk
population; moderate-certainty evidence).
When using a VKA or LMWH for a longer course of anticoagulation,
there was a reduction in the risk of DVT without statistical
significance for the study population (RR, 0.60; 95% CI, 0.32 to
1.11; ARR, 64 fewer per 1000 patients; 95% CI, 109 fewer to 18
more), as well as for a low-risk population (ARR, 21 fewer per 1000
patients; 95% CI, 36 fewer to 6 more; moderate-certainty
evidence). Similar outcomes were seen for the risk of PE for the
study population (RR, 0.84; 95% CI, 0.43-1.66; ARR, 13 fewer per
1000 patients; 95% CI, 47 fewer to 55 more), as well as for a low-
risk population274 (ARR, 7 fewer per 1000 patients; 95% CI, 25
fewer to 29 more; moderate-certainty evidence).
Harms and burden. Our analysis showed a potential increase in
mortality when using a longer course of anticoagulation compared
with a shorter course for primary treatment, without statistical
significance (RR, 1.38; 95% CI, 0.85-2.23; ARR, 7 more per 1000
patients; 95% CI, 3 fewer to 22 more; moderate-certainty
evidence).
The use of a longer course of anticoagulant therapy may
increase the risk of major bleeding (RR, 1.46; 95% CI, 0.78-
2.73; ARR, 6 more per 1000 patients; 95% CI, 3 fewer to 22
more; moderate-certainty evidence). In populations with a low
risk for bleeding,98 the use of a longer course of anticoagulation
instead of a shorter course may lead to an increase of 10 more
bleeding events per 1000 patients (95% CI, 5 fewer to 36 more;
moderate-certainty evidence).
Certainty in the evidence of effects. The certainty in the
evidence was judged moderate for mortality, PE, and major
bleeding because of imprecision, given that the CI around the
absolute estimates likely crossed the thresholds that patients
would consider important. Therefore, it was not possible to
completely rule out a small difference between the alternatives
on such outcomes. For DVT, the certainty in the evidence was
judged high. In the subgroup analysis performed, there were 2
cases in which the quality of the evidence differed from the
original analysis. Both of these were on the outcome when using
VKA, LMWH, or DOAC. The certainties of the evidence were
judged moderate because of imprecision.
Other EtD criteria and considerations. We considered that
avoidance of PE, DVT, and bleeding was critical for patients.
However, there may be important variability in how individual
patients value the risk of thrombosis vs the risk of bleeding.
We did not identify direct evidence on a cost-effectiveness
comparison for nonsurgical provoked DVT/PE. Four Markov
model analyses of cost-effectiveness for extended antithrom-
botic therapy vs limited antithrombotic therapy for VTE
treatment were identified. Three analyses showed that a longer
course of anticoagulation was cost-effective compared with
a shorter course of antithrombotic therapy,112,270,271 whereas
1 analysis suggested that a longer course of anticoagulation
with warfarin was cost-effective in younger patients, and
3 months of anticoagulation was preferred in elderly patients
(age $80 years).272
The panel considered that a longer course of anticoagulation was
probably acceptable and feasible. Observational studies suggested
a higher level of patient satisfaction with a DOAC and a lower
treatment burden than with LMWH or a VKA.273
Conclusions and implementation considerations. Acquired
(environmental) risk factors for DVT and/or PE that are consid-
ered chronic include cancer (discussed in a future guideline
document from ASH), certain autoimmune disorders (eg, in-
flammatory bowel disease or antiphospholipid syndrome), and
chronic immobility (Table 3).237 Some of these risk factors may
fluctuate over time (eg, the autoimmune disorders), but many of
these patients are considered to be at a higher risk for recurrent
thromboembolism if anticoagulant therapy is discontinued. As
noted in the previous recommendation, any benefit associated
with a longer finite course of therapy is lost after anti-
coagulation is discontinued. For primary treatment of the
thromboembolic event, the ASH guideline panel has provided
a conditional recommendation for a shorter course (3-6
months) of therapeutic anticoagulation over a longer course
(6-12 months) of therapy, based on moderate certainty in the
evidence of effects. After completion of the primary treatment
phase, subsequent decisions (discussed in Recommendation
18) would determine whether to discontinue anticoagulant
therapy or continue it indefinitely for secondary prevention of
recurrent VTE (Figure 2).
It should be noted that patients with chronic risk factors for VTE may
also have 1 (or more) transient risk factor (eg, surgery) or other
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nonenvironmental risk factors, such as an inherited thrombophilia,
older age, or male sex.237 These additional risk factors do not
change this recommendation for duration of the primary treatment
phase for the thromboembolic event.
Recommendation 14, primary treatment for patients
with unprovoked DVT and/or PE
Summary of the evidence. We identified 19 systematic
reviews239-257 and 10 RCTs258-267 (n 5 2857). One set of trials
included adults with objectively confirmed DVT and/or PE at the
time of diagnosis who were randomized to receive a shorter course
(3-6 months) or a longer course (.6 months) of anticoagulation. A
second set of trials included adults with objectively confirmed DVT
and/or PE who had been treated with anticoagulants for 3 to
6 months without recurrence; they were randomized to receive
placebo or continue with $6 months of additional treatment. The
longer course of therapy varied from 6 months to 24 months.262
Patients were continuously followed up after completion of the
longer course of anticoagulation treatment. The outcomes were
measured in both groups at the end of the follow-up. For baseline
risks of VTE, we used a meta-analysis of 10 cohort studies and 5
randomized trials268 that reported a risk of recurrent VTE of 7.4
per 100 patient-years for patients with unprovoked VTE.
Assuming that 45% of the VTE events are PEs and 55% are
DVTs,269 we estimated annualized risks of recurrent PE of 3.3
and of recurrent DVT of 4.1 per 100 patient-years for patients
with unprovoked VTE. For the baseline risk of major bleeding, we
used a meta-analysis of 13 prospective cohort studies and 56
randomized trials98 in VTE patients showing a 2.1% risk for major
bleeding during a 6-month period of treatment with anticoagulants.
We estimated an annualized risk for major bleeding of 2.1%
assuming a risk for major bleeding close to 0 after anticoagulant
discontinuation. The EtD framework is shown online at: https://
guidelines.gradepro.org/profile/ADBCBA97-1E09-37C6-B664-
D6FD9A489DC3.
Benefits. The meta-analysis showed that, compared with a short-
er course of anticoagulation, treating patients with a longer course
of anticoagulation reduced the risk of DVT (RR, 0.50; 95%CI, 0.27-
0.95; ARR, 59 fewer per 1000 patients; 95% CI, 86 fewer to 6
fewer; high-certainty evidence). In a low-risk population,268 a longer
course of anticoagulant therapy reduced the risk of DVT as well
(ARR, 20 fewer per 1000 patients; 95% CI, 30 fewer to 2 fewer). A
longer course of anticoagulation also showed a potential reduction
in the risk of PE in the study population, without statistical
significance (RR, 0.66; 95% CI, 0.29-1.51; ARR, 17 fewer per
1000 patients; 95% CI, 35 fewer to 25 more; moderate-certainty
evidence), and likely a small reduction in a low-risk population268
(ARR, 11 fewer per 1000 patients; 95% CI, 24 fewer to 17 more;
moderate-certainty evidence). When using a DOAC for a longer
course of anticoagulation, the risk of DVT was reduced in the study
population (RR, 0.21; 95% CI, 0.11-0.41; ARR, 62 fewer per 1000
patients; 95% CI, 70 fewer to 46 fewer; high-certainty evidence),
as well as in a low-risk population268 (ARR, 32 fewer per 1000
patients; 95% CI, 36 fewer to 24 fewer; moderate-certainty
evidence). A longer course of therapy with a DOAC also reduced
the risk of PE for the study population (RR, 0.13; 95% CI, 0.03-
0.58; ARR, 21 fewer per 1000 patients; 95% CI, 24 fewer to 10
fewer), as well as for a low-risk population (ARR, 29 fewer per
1000 patients; 95% CI, 32 fewer to 14 fewer; moderate-
certainty evidence).
When using a VKA or LMWH for a longer course of anticoagulation,
there was a reduction in the risk of DVT without statistical
significance for the study population (RR, 0.60; 95% CI, 0.32-
1.11; ARR, 64 fewer per 1000 patients; 95% CI, 109 fewer to 18
more), as well as for a low-risk population (ARR, 16 fewer per 1000
patients; 95% CI, 28 fewer to 4 more; moderate-certainty
evidence), and likely a small reduction in the risk of PE for the
study population (RR, 0.84; 95% CI, 0.43-1.66; ARR, 13 fewer per
1000 patients; 95% CI, 47 fewer to 55 more), as well as for a low-
risk population268 (ARR, 5 fewer per 1000 patients; 95% CI, 19
fewer to 22 more; moderate-certainty evidence).
Harms and burden. Our analysis showed a potential increase in
mortality when using a longer course of anticoagulation compared
with a shorter course of anticoagulation, without statistical
significance (RR, 1.38; 95% CI, 0.85-2.23; ARR, 7 more per
1000 patients; 95% CI, 3 fewer to 22 more; moderate-certainty
evidence).
The use of a longer course of anticoagulant therapy may increase
the risk of major bleeding (RR, 1.46; 95% CI, 0.78-2.73; ARR, 6
more per 1000 patients; 95% CI, 3 fewer to 22 more; moderate-
certainty evidence). In populations with a low risk for bleeding,98 the
use of a longer course of anticoagulation instead of a shorter course
may lead to an increase of 10 more bleeding events per 1000
patients (95% CI, 5 fewer to 36 more; moderate-certainty evidence).
Certainty in the evidence of effects. The certainty in the
evidence was judged moderate for mortality, PE, and major bleeding
because of imprecision, given that the CI around the absolute
estimates likely crossed the thresholds that patients would consider
important. Therefore, it was not possible to completely rule out
a small difference between the alternatives on such outcomes. For
DVT, the certainty in the evidence was judged high. In the subgroup
analysis performed, there were 2 cases in which the quality of the
evidence differed from the original analysis. Both of these involved
the DVT outcome when using VKAs/LMWH or DOACs. The
certainties in the evidence were judged moderate because of
imprecision.
Other EtD criteria and considerations. We considered that
avoidance of PE, DVT, and bleeding was critical for patients.
However, there is important variability in how individual patients may
value the risk of thrombosis vs the risk of bleeding.
We did not identify direct evidence for a cost-effectiveness
comparison for unprovoked VTE. Four Markov model analyses of
cost-effectiveness for a longer course of anticoagulant therapy vs
a shorter course of anticoagulant therapy for VTE treatment were
identified. Three analyses showed that the longer course of
anticoagulant therapy was cost-effective compared with the shorter
course of therapy,112,270,271 whereas 1 analysis suggested that
a longer course of anticoagulation with warfarin was cost-effective
in younger patients, and 3 months of anticoagulation was preferred
in elderly patients ($80 years).272
The panel considered that a longer course of anticoagulant therapy
was probably acceptable and feasible. An observational study
suggested a higher level of patient satisfaction with a DOAC and
a lower treatment burden than with LMWH or a VKA.273
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Conclusions and implementation considerations. A DVT
and/or PE that occurs in the absence of any transient or chronic
environmental risk factors for VTE is considered unprovoked.
These patients are considered to be at a higher risk for recurrent
thromboembolism if anticoagulant therapy is discontinued. In
addition, as noted above, any benefit associated with a longer
finite course of therapy is lost after anticoagulation is discon-
tinued. For primary treatment of the thromboembolic event, the
ASH guideline panel has provided a conditional recommendation
for a shorter course (3-6 months) of therapeutic anticoagulation
over a longer course (6-12 months) of therapy, based on
moderate certainty in the evidence of effects. These patients
may have$1 nonenvironmental risk factor for recurrent VTE, such
as inherited thrombophilia, older age, and/or male sex, but these
variables would not affect this recommendation concerning the
duration of the primary treatment phase for the thromboembolic
event. After completion of the primary treatment phase, sub-
sequent decisions (discussed in Recommendation 19) would
determine whether to discontinue anticoagulant therapy or
continue indefinitely for secondary prevention of recurrent VTE
(Figure 2).
Secondary prevention. This section covers the phase of
treatment identified as secondary prevention in Figures 1 and 2.
This phase occurs after the patient has completed an initial course
of anticoagulant therapy, referred to as primary treatment, at which
time the patient will discontinue anticoagulation or continue without
a predefined stop date. Recommendations 15 to 17 address the
use of various tools to assist in the decision-making process
concerning whether to discontinue anticoagulant therapy. Recom-
mendations 18 and 19 address whether patients with VTE
associated with chronic risk factors and patients with unprovoked
VTE, who have completed primary treatment, should discontinue
anticoagulation or consider an indefinite course of therapy.
Recommendations 20 to 22 address the antithrombotic therapies
that might be considered for patients who continue indefinite
therapy.
Recommendations 15, 16, and 17
For patients with unprovoked DVT and/or PE, the ASH
guideline panel suggests against routine use of prognostic
scores (Recommendation 15), D-dimer testing (Recommen-
dation 16), or ultrasound to detect residual vein thrombosis
(Recommendation 17) to guide the duration of anticoagulation
(conditional recommendations based on very low certainty in
the evidence of effects Å○○○).
Remarks: Indefinite anticoagulation is probably appropriate
for the majority of patients with unprovoked VTE. However, in
certain circumstances, such as when patients are undecided or
the balance between risks and benefits is uncertain, clinicians
and patients may use prognostic scores, the D-dimer test, or
ultrasound assessment for residual thrombosis from an initial
DVT to aid in reaching a final decision. Recommendations 15 to
17 address the routine use of these strategies.
Summary of the evidence
We identified 1 systematic review evaluating prognostic scores,275
which included 20 observational studies.276-293 Additionally, we
identified 4 systematic reviews294-297 and 1 relevant randomized
trial298 assessing the role of D-dimer testing, as well as 5 systematic
reviews299-303 and 1 relevant trial304 evaluating the use of
ultrasound assessment for residual thrombosis from an initial DVT
to guide the duration of anticoagulation.
The ideal way to measure the impact of various tools on patient-
important outcomes would be to randomize patients to a decision
guided by the tool or to a decision guided by specific guidelines
without knowledge of the tool prediction. Unfortunately, such
evidence is rare. We identified only 1 randomized trial304 that was
designed this way; after the completion of 3 months of anti-
coagulation, 538 patients with DVT were randomized to anti-
coagulation for a fixed period of time or to ultrasonography-guided
anticoagulation (no further anticoagulation for patients with
recanalized veins and continued anticoagulation for patients with
residual thrombosis). Another trial,298 close to the ideal design,
included 223 individuals with an elevated D-dimer 1 month after
completing 3 to 6 months of anticoagulation. In this study,
participants were randomized to stop anticoagulation or to
continue it for up to 18 months.
We did find studies evaluating the prognostic performance of the
different tools: an individual patient meta-analysis of observational
studies and 1 RCT (n 5 2527)300 showed an independent
association of residual vein thrombosis and recurrent VTE (HR,
1.32; 95% CI, 1.06-1.65). Another individual patient meta-analysis
of 7 observational studies (n5 1818)296 showed that, after an initial
period of anticoagulation, individuals with persistently elevated
D-dimer levels have an increased risk for recurrent VTE (HR, 2.59;
95% CI, 1.90-3.52). Finally, the systematic review of prognostic
models275 identified 3 scores: HERDOO2, Vienna, and DASH.
The 3 models include D-dimer testing but differ with regard to the
additional clinical characteristics considered. The Vienna score
has been studied more and has showed moderate discrimination
(c-statistic, 0.6) and a tendency to underestimate the true risk of






In the trial assessing the role of residual vein thrombosis,304
participants randomized to ultrasonography received anticoagula-
tion for an average of 4 to 5 months longer than did individuals
randomized to the control group. Consequently, the investigators
observed a nonsignificant reduction in the risk of PE (RR, 0.75;
95% CI, 0.21-2.60; ARR, 6 fewer per 1000 patients; 95% CI, 17
fewer to 35 more; low-certainty evidence) and DVT (RR, 0.64; 95%
CI, 0.37-1.12; ARR, 16 fewer per 1000 patients; 95% CI, 28 fewer
to 5 more; low-certainty evidence) in the intervention group.
In the trial that randomized individuals with high D-dimer levels298 to
continue or to stop anticoagulation, the use of extended anti-
coagulation was associated with a reduction in PEs (RR, 0.16; 95%
CI, 0.02-1.33; ARR, 8 fewer per 1000 patients; 95% CI, 10 fewer
to 3 more; very-low-certainty evidence) and DVTs (RR, 0.07; 95%
CI, 0.01-0.58; ARR, 9 fewer per 1000 patients; 95% CI, 4 to 10
fewer; very-low-certainty evidence).
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Harms and burden
In the trial evaluating residual vein thrombosis by ultrasonography,
participants in the intervention group received anticoagulation for
an average of 4 to 5 months longer than did controls. Hence, they
had a higher risk for bleeding (RR, 1.99; 95%CI, 0.37-10.7; ARR, 2
more per 1000 patients; 95% CI, 1 fewer to 20 more; low-certainty
evidence).
Also, in the trial randomizing individuals with high D-dimer levels to
continue or to stop anticoagulation, extended anticoagulation was
associated with a higher risk for bleeding (RR, 3.49; 95% CI, 0.14-
84.76; ARR, 24 more per 1000 patients; 95% CI, 8 fewer to 813
more; very-low-certainty evidence).
We did not find any randomized clinical trials investigating the
prognostic scores that compared patient-important outcomes.
Certainty in the evidence of effects
We judged the certainty in the evidence as low for the use of
ultrasonography and as very low for the use of D-dimer and
prognostics scores. In the first case, we only found 1 trial comparing
fixed periods of anticoagulation with ultrasonography-guided
duration for patients without cancer. We rated down the certainty
in the evidence for risk of bias, given that the trial was open label,
and for imprecision, because the CIs around the absolute estimates
include benefit and harm.
In the case of D-dimer, we also rated down the certainty in the
evidence for risk of bias (unblinded study) and imprecision (wide CIs
around absolute estimates). However, we rated down the certainty
in the evidence 1 additional step because of indirectness, given that
the trial identified did not really test the use of the D-dimer to make
the decision whether to stop or continue anticoagulation. Rather,
the study assessed the effect of anticoagulation in individuals with
a high D-dimer level, which is a related question but not the specific
question addressed by the panel.
As noted above, in the case of prognostic scores, at the time of
our systematic review, we did not find any trial assessing their
impact in patient-important outcomes, and the evidence re-
garding their discrimination ability and their validation was limited.
Subsequently, a study investigating the HERDOO2 rule showed
that women with a first unprovoked VTE and 0 or 1 of the
HERDOO2 criteria could safely discontinue anticoagulant therapy
after completing 5 to 12 months of therapeutic anticoagulation as
primary treatment.305
Other EtD criteria and considerations
We did not identify any relevant economic evaluation; however, we
considered the cost of using ultrasonography or D-dimer as
moderate. Both tests are generally available, but ultrasonography
is operator dependent and, therefore, results might vary in different
settings.
Conclusions and implementation considerations
For the individual patient who has completed primary treatment of
their VTE, information from 1 of the prognostic tools, a D-dimer, and/
or an ultrasound assessment may be valuable for the provider and/
or the patient in the decision-making process. The ASH guideline
panel provides a conditional recommendation against the routine
use of any of these modalities for all patients with VTE but
acknowledges the potential utility of 1 (or more) of these approaches
for management of individual patients.
The panel felt that an important research question concerning the
use of prognostic scores, D-dimer testing, and/or ultrasound
centered around the identification of which patient populations
would benefit most from the incorporation of$1 of these strategies
into the decision-making process concerning whether anticoagu-
lant therapy should be continued after completion of the primary
treatment phase of therapy.
Recommendation 18
After completion of primary treatment for patients with
DVT and/or PE provoked by a chronic risk factor, the ASH
guideline panel suggests indefinite antithrombotic therapy
over stopping anticoagulation (conditional recommenda-
tion based on moderate certainty in the evidence of effects
ÅÅÅ○).
Remarks: Patients with DVT and/or PE provoked by a tran-
sient risk factor typically do not require antithrombotic therapy
after completion of primary treatment. This recommendation
refers to patients with DVT and/or PE provoked by a chronic
persistent risk factor (eg, inflammatory bowel disease or auto-
immune disease). However, this recommendation does not
apply to patients who have a high risk for bleeding complica-
tions. For guidance on selection of antithrombotic therapy after
completion of primary treatment, see Recommendation 20.
Decisions regarding anticoagulation in individuals with cancer
are discussed in a future guideline from ASH.
Summary of the evidence
We identified 19 systematic reviews239-257 and 13
RCTs88,258,259,261,262,265,267,298,306-310 (n 5 8593) to inform this
recommendation. Trials included adults with objectively confirmed
DVT and/or PE who had been treated with anticoagulants for
$3 months without recurrence. Patients were randomized to
receive placebo or continue treatment for $6 months. The mean
follow-up time varied from 24 to 28 months for different outcomes.
The outcomes were measured in both groups immediately at the
end of the extended-duration treatment. For baseline risks of VTE,
we used a multicenter prospective cohort study274 that included
646 participants and reported a 9.7% per patient-year VTE
recurrence rate for patients with a chronic risk factor. Assuming
that 45% of the initial VTE events are PEs and 55% are DVTs,269
we estimated annualized risks of 4.4 and 5.3 per 100 patient-years
for PE and DVT recurrence, respectively, for patients with
a chronic risk factor. For the baseline risk of major bleeding, we
used data from 2 randomized trials on people with VTE, showing
that the risk of major bleeding with placebo during 18 or
24 months of follow-up was as low as 0.5%306 and as high as




The meta-analysis showed that, compared with discontinuation of
anticoagulation, treating patients with indefinite antithrombotic
therapy reduced the risk of PE in the study population (RR, 0.29;
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95% CI, 0.15-0.56; ARR, 21 fewer per 1000 patients; 95% CI, 25
fewer to 13 fewer; high-certainty evidence), as well as for patients
with chronic risk factors269,274 (ARR, 31 fewer per 1000 patients;
95% CI, 37 fewer to 19 fewer; high-certainty evidence). Indefinite
antithrombotic therapy also showed a reduced risk for DVT in the study
population (RR, 0.20; 95% CI, 0.12-0.34; ARR, 50 fewer per 1000
patients; 95% CI, 56 fewer to 42 fewer; high-certainty evidence), as
well as for patients with chronic risk factors at 1 year269,274 (ARR, 45
fewer per 1000 patients; 95% CI, 48 fewer to 41 fewer).
There were significant subgroup effects with different antithrom-
botic interventions on DVT outcome. When using DOACs for
indefinite anticoagulation, the risk of DVT in the study population
was reduced (RR, 0.15; 95% CI, 0.10-0.23; ARR, 49 fewer per
1000 patients; 95% CI, 51 fewer to 44 fewer; high-certainty
evidence), as well as for patients with chronic risk factors (ARR, 45
fewer per 1000 patients; 95% CI, 48 fewer to 41 fewer; high-
certainty evidence).269,274 When using a VKA or LMWH for
indefinite anticoagulation, a reduction in the risk of DVT for the
study population was observed (RR, 0.17; 95%CI, 0.05-0.53; ARR,
54 fewer per 1000 patients; 95% CI, 61 fewer to 30 fewer), as well
as for patients with chronic risk factors269,274 (ARR, 44 fewer per
1000 patients; 95% CI, 51 fewer to 25 fewer; high-certainty
evidence). Aspirin reduced the risk of DVT in the study population
(RR, 0.55; 95% CI, 0.31-0.98; ARR, 64 fewer per 1000 patients;
95% CI, 98 fewer to 3 fewer), as well as for patients with chronic
risk factors269,274 (ARR, 24 fewer per 1000 patients; 95% CI, 37
fewer to 1 fewer; moderate-certainty evidence). Our analysis
showed a potential decrease in mortality when using indefinite
antithrombotic therapy compared to a defined duration of anti-
coagulation, but without statistical significance (RR, 0.75; 95% CI,
0.49-1.13; ARR, 4 fewer per 1000 patients; 95% CI, 8 fewer to 2
more; moderate-certainty evidence).
Harms and burden
The use of indefinite antithrombotic therapy increased the risk of
major bleeding (RR, 2.17; 95% CI, 1.40-3.35; ARR, 6 more per
1000 patients; 95% CI, 2 more to 12 more; high-certainty
evidence). In populations with a high risk for bleeding, the use of
indefinite therapy instead of a defined duration of anticoagulation
led to an increase of 18 more bleeding events per 1000 patients
(95% CI, 6 more to 35 more; high-certainty evidence).
Certainty in the evidence of effects
The certainty in the evidence was judged high for PE, DVT, and
major bleeding but moderate for mortality because of imprecision,
given that the CI around the absolute estimates likely crossed the
thresholds that patients would consider important. Therefore, it was
not possible to completely rule out a small difference between the
alternatives on mortality. In the subgroup analysis performed for
DVT when using aspirin, the certainty in the evidence was judged
moderate because of imprecision.
Other EtD criteria and considerations
We considered that avoidance of PE, DVT, and major bleeding was
critical for patients. Patients placed a high value on the benefits of
risk reduction in VTE recurrence and PTS.311 However, there is
important variability in how individual patients may value the risk of
recurrent VTE vs the risk of bleeding.
We did not identify direct evidence on a cost-effectiveness
comparison for VTE provoked by a chronic risk factor. Four Markov
model analyses of cost-effectiveness for extended antithrombotic
therapy vs limited antithrombotic therapy for VTE treatment were
identified. Three analyses showed cost-effectiveness for the
extended strategy compared with the limited antithrombotic
strategy,112,270,271 whereas 1 analysis suggested that longer initial
conventional-intensity anticoagulation with warfarin was cost-
effective in younger patients and 3 months of anticoagulation was
preferred in elderly patients ($80 years old).272 The panel
considered that cost-effectiveness varies with patients, the chronic
risk factor(s) contributing to the increased risk of recurrent VTE,
and the antithrombotic used.
The panel considered that indefinite treatment was probably
feasible, but that acceptability varies.
Conclusions and implementation considerations
Patients with a chronic (“persistent”) risk factor, such as in-
flammatory bowel disease or an autoimmune disorder, who sustain
a VTE are considered to be at higher risk for recurrence if
anticoagulation is discontinued after completion of the primary
treatment phase compared with patients who have a transient risk
factor. For patients with a chronic risk factor, the ASH guideline
panel has provided a conditional recommendation for continuing
antithrombotic therapy indefinitely after completion of primary
treatment. Additional factors that may be useful for evaluation of
the individual patient would include whether a transient risk factor
was also present prior to the event and whether the patient has
comorbid conditions that may predispose toward an increased risk
for bleeding complications. Risk factors for bleeding with antico-
agulant therapy include, but are not limited to, older age, history of
prior bleeding, cancer, hepatic and/or renal insufficiency, hyperten-
sion, thrombocytopenia, prior stroke, need for antiplatelet therapy,
anemia, alcohol abuse, and frequent falls.312 An individual patient’s
risk for bleeding will be affected by the severity of the risk factor (eg,
degree of thrombocytopenia, location and extent of metastatic
cancer), the number of risk factors present, and the presence of
additional comorbid conditions. All patients who choose indefinite
antithrombotic therapy for secondary prevention of recurrent VTE
should be reevaluated at least annually to review their clinical
course and reassess the clinical indication for continued indefinite
therapy and bleeding risk factors.
The panel felt that additional research was needed to better define
the impact of different chronic risk factors on the rate of recurrent
VTE, particularly if the risk might vary over time.
Recommendation 19
After completion of primary treatment for patients with un-
provoked DVT or PE, the ASH guideline panel suggests in-
definite antithrombotic therapy over stopping anticoagulation
(conditional recommendation based on moderate certainty in
the evidence of effects ÅÅÅ○).
Remarks: This recommendation does not apply to patients
who have a high risk for bleeding complications. For guidance
on selection of antithrombotic therapy after completion of pri-
mary treatment, see Recommendation 20.
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Summary of the evidence
We identified 19 systematic reviews239-257 and 13
RCTs88,258,259,261,262,265,267,298,306-310 (n 5 8593) to inform this
recommendation. Trials included adults with objectively confirmed
DVT or PE who had been treated with anticoagulants for
$3 months without recurrence. Patients were randomized to
receive placebo or continue with extended treatment for $6
months. The mean follow-up varied from 24 months to 28 months
for different outcomes. The outcomes were measured in both
groups immediately at the end of the extended-duration treatment.
For baseline risks of VTE, we used a meta-analysis of 10 cohort
studies and 5 randomized trials268 that reported a risk for recurrent
VTE of 7.4% per patient-year for patients with unprovoked VTE.
Assuming that 45% of the initial VTE events are PEs and 55% are
DVTs,269 we estimated annualized risks of 3.3 and 4.1 per
100 patient-years for PE and DVT recurrence, respectively, for
patients with an unprovoked VTE. For the baseline risk of major
bleeding, we used data from 2 randomized trials on people with
VTE, which showed that the risk of major bleeding with placebo
during 18 months or 24 months of follow-up was as low as 0.5%306




The meta-analysis showed that, compared with discontinuation of
anticoagulation, treating patients with indefinite antithrombotic
therapy reduced the risk of PE in the study population (RR, 0.29;
95% CI, 0.15-0.56; ARR, 21 fewer per 1000 patients; 95% CI, 25
fewer to 13 fewer; high-certainty evidence), as well as for patients
with unprovoked VTE269,274 (ARR, 24 fewer per 1000 patients;
95% CI, 28 fewer to 15 fewer; high-certainty evidence). Indefinite
antithrombotic therapy also showed a risk for reduction of DVT in
the study population (RR, 0.20; 95% CI, 0.12-0.34; ARR, 50 fewer
per 1000 patients; 95% CI, 56 fewer to 42 fewer; high-certainty
evidence), as well as for patients with unprovoked VTE at
1 year269,274 (ARR, 33 fewer per 1000 patients; 95% CI, 36 fewer
to 27 fewer).
There were significant subgroup effects of different antithrombotic
interventions on DVT outcome. When using a DOAC for indefinite
anticoagulation, the risk of DVT was reduced in the study population
(RR, 0.15; 95% CI, 0.10-0.23; ARR, 49 fewer per 1000 patients;
95% CI, 51 fewer to 44 fewer; high-certainty evidence), as well as
for patients with unprovoked VTE269,274 (ARR, 35 fewer per 1000
patients; 95% CI, 37 fewer to 31 fewer; high-certainty evidence).
When using a VKA or LMWH for indefinite anticoagulation, the risk
of DVT was likely reduced in the study population (RR, 0.17; 95%
CI, 0.05-0.53; ARR, 54 fewer per 1000 patients; 95% CI, 61 fewer
to 30 fewer; moderate-certainty evidence), as well as for patients
with unprovoked VTE (ARR, 34 fewer per 1000 patients, 95% CI,
39 fewer to 19 fewer; high-certainty evidence).269,274 Aspirin also
likely reduced the risk of DVT for the study population (RR, 0.55;
95% CI, 0.31-0.98; ARR, 64 fewer per 1000 patients, 95% CI, 98
fewer to 3 fewer; moderate-certainty evidence), as well as for
patients with unprovoked VTE (ARR, 18 fewer per 1000 patients;
95% CI, 28 fewer to 1 fewer; moderate-certainty evidence).269,274
Our analysis showed a nonsignificant decrease in mortality when
using indefinite antithrombotic therapy compared with a defined
duration of anticoagulation (RR, 0.75; 95% CI, 0.49-1.13; ARR, 5
fewer per 1000 patients; 95% CI, 9 fewer to 2 more; moderate-
certainty evidence).
Harms and burden
Indefinite antithrombotic therapy increased the risk of major
bleeding (RR, 2.17; 95% CI, 1.40-3.35; ARR, 6 more per 1000
patients; 95% CI, 2 more to 12 more; high-certainty evidence). In
populations with a high risk for bleeding, the use of indefinite
antithrombotic therapy instead of a defined duration of anti-
coagulation led to an increase of 18 more bleeding events per
1000 patients (95% CI, 6 more to 35 more; high-certainty
evidence).
Certainty in the evidence of effects
The certainty in the evidence was judged high for PE, DVT, and
major bleeding but moderate for mortality because of imprecision,
given the CI around the absolute estimates likely crossed the
thresholds that patients would consider important. Therefore, it was
not possible to completely rule out a small difference between the
alternatives on mortality. In the subgroup analysis performed for
recurrent DVT when using aspirin, the certainty in the evidence was
judged moderate because of imprecision.
Other EtD criteria and considerations
We considered that avoidance of PE, DVT, and major bleeding was
critical for patients. Patients placed a high value on the benefits of
risk reduction in VTE recurrence and PTS.311 However, there is
important variability in how individual patients may value the risk of
recurrent VTE vs the risk of bleeding.
We did not identify direct evidence on a cost-effectiveness
comparison for unprovoked VTE. Four Markov model analyses of
cost-effectiveness for extended antithrombotic therapy vs limited
antithrombotic therapy for VTE treatment were identified. Three
analyses showed that the extended strategy was cost-effective
compared with limited antithrombotic therapy,112,270,271 whereas 1
analysis suggested that longer initial conventional-intensity anti-
coagulation with warfarin was cost-effective in younger patients and
3 months of anticoagulation was preferred in elderly patients (80-
year-old subgroup).272 The panel considered that cost-effectiveness
varies with patients, any risk factor(s) contributing to the increased
risk of recurrent VTE, and the specific anticoagulant used.
The panel considered that indefinite treatment was probably
feasible but that the acceptability varies.
Conclusions and implementation considerations
Patients with unprovoked VTE, defined as occurring in the absence
of any identifiable transient or chronic acquired risk factors, have the
highest risk for recurrent VTE if anticoagulation is discontinued after
the primary treatment phase. This risk has been estimated to be as
high as 10% by 1 year and up to 30% by 5 to 10 years.10,11,313 The
ASH guideline panel has provided a conditional recommendation
for continuing antithrombotic therapy indefinitely after completion of
primary treatment for patients with unprovoked VTE, based on
moderate certainty in the evidence of effects. All patients who are
recommended to take indefinite antithrombotic therapy for second-
ary prevention of recurrent VTE should be reevaluated at least
annually to review the clinical indication for indefinite therapy and
any bleeding complications that the patient may have sustained or
new bleeding risk factors that the patient may have acquired.
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As noted above in Recommendation 18, risk factors for bleeding
with anticoagulant therapy include, but are not limited to, older
age, history of prior bleeding, cancer, hepatic and/or renal
insufficiency, hypertension, thrombocytopenia, prior stroke, need
for antiplatelet therapy, anemia, alcohol abuse, and frequent
falls.312 An individual patient’s risk for bleeding will be affected
by the severity of the risk factor (eg, degree of thrombocyto-
penia, location and extent of metastatic cancer), the number of
risk factors present, and the presence of additional comorbid
conditions.
Recommendation 20
For patients with DVT and/or PE who have completed primary
treatment and will continue to receive secondary prevention,
the ASH guideline panel suggests using anticoagulation over
aspirin (conditional recommendation based on moderate cer-
tainty in the evidence of effects ÅÅÅ○).
Summary of the evidence
We identified 1 RCT317 to inform this recommendation. This trial
included adults with objectively confirmed DVT and/or PE who
had been treated with a DOAC or VKA for 6 to 12 months
and had not interrupted therapy for more than 7 days prior to
randomization. Patients were randomized to receive 20 mg of
rivaroxaban or 100 mg of aspirin for 12 months. For the
purpose of this question, aspirin was considered the interven-
tion, and rivaroxaban was the comparator. The mean follow-up




The analysis showed that, compared with a standard dose of
anticoagulation, treating patients with aspirin may reduce the risk of
major bleeding, but these results are not statistically significant (RR,
0.49; 95% CI, 0.12-1.95; ARR, 3 fewer per 1000 patients; 95% CI,
5 fewer to 5 more; moderate-certainty evidence).
Harms and burden
The use of aspirin compared with a standard dose of anti-
coagulation increased the risk of nonfatal PE (RR, 3.10; 95% CI,
1.24-7.73; ARR, 11 more per 1000 patients; 95% CI, 1 more to 36
more; moderate-certainty evidence) or DVT (RR, 3.15; 95% CI,
1.50-6.63; ARR, 17 more per 1000 patients; 95% CI, 4 more to 46
more; moderate-certainty evidence).
Certainty in the evidence of effects
The certainty in the evidence was judged moderate for mortality,
major bleeding, PE, and DVT because of imprecision, given a small
number of events in both treatment arms that did not meet the
optimal information size and the fact that the CIs around the
absolute estimates likely crossed the thresholds that patients would
consider important.
Other EtD criteria and considerations
We considered that the avoidance of PE, DVT, and major
bleeding was critical for patients. Patients placed a high value
on the benefits of risk reduction in VTE recurrence and PTS.311
However, there is important variability in how individual patients
may value the risk of recurrent VTE vs the risk of bleeding. The
panel considered the variability of the cost of drugs across
different countries and felt that the cost of anticoagulants,
specifically DOACs, compared with aspirin would place at least
a moderate burden on patients.
The panel considered that switching patients to aspirin at the
completion of primary therapy was probably feasible and probably
acceptable to relevant stakeholders.
Conclusions and implementation considerations
Extending anticoagulant therapy beyond the primary treatment
phase reduces the risk of recurrent VTE but is associated with
an increased risk for bleeding complications. Consequently,
several studies have investigated the role of aspirin for the
secondary prevention of VTE.309,314,315 The WARFASA309 and
ASPIRE318 trials compared aspirin, 100 mg daily, with placebo
for secondary prevention of recurrent VTE for patients with
an initial unprovoked event, and the pooled results of the 2
trials showed a decrease in recurrent VTE, as well as major
vascular events, without an increased risk for clinically rele-
vant bleeding.309,315 However, a systematic review and meta-
analysis comparing extended anticoagulant therapy and aspirin
found that anticoagulant therapy was more effective than
aspirin in preventing recurrent VTE,246 and a single study
comparing 2 doses of the direct oral anticoagulant rivaroxaban
and aspirin found that anticoagulation was more effective than
aspirin without an increase in bleeding rates.314 Consequently,
the ASH guideline panel has provided a conditional recom-
mendation supporting the use of anticoagulation over aspirin
for secondary prevention of VTE. For patients who are going
to discontinue anticoagulant therapy after completion of the
primary treatment phase, the role of aspirin can be consid-
ered but needs to be individualized. The panel did not address
other nonanticoagulant options for secondary prevention of
recurrent VTE.
Recommendation 21
For patients with DVT and/or PE who have completed primary
treatment and will continue VKA therapy as secondary pre-
vention, the ASH guideline panel recommends using an INR
range of 2.0 to 3.0 over a lower INR range (eg, 1.5-1.9) (strong
recommendation based on moderate certainty in the evidence
of effects ÅÅÅ○).
Summary of the evidence
We identified 1 RCT316 to inform this recommendation. This trial
included adults with objectively confirmed unprovoked DVT and/or
PE who had been treated with oral anticoagulants for$at least 3
months. Patients were randomized to receive low-intensity
warfarin therapy (target INR, 1.5-1.9) or conventional-intensity
warfarin therapy (target INR, 2.0-3.0) after completion of the
primary treatment phase of therapy. Patients were followed for
an average of 2.4 years. The EtD framework is shown online at:






















We did not identify any benefits associated with use of a lower
INR range.
Harms and burden
The use of warfarin with an INR range lower than 2.0 to 3.0 may
increase the risk of DVT (RR, 3.25; 95% CI, 1.07-9.87; ARR, 24
more per 1000 patients; 95% CI, 1 more to 96 more; moderate-
certainty evidence) and may increase the risk of nonfatal PE
(RR, 5.0; 95% CI, 0.24-103.79; ARR could not be estimated;
moderate-certainty evidence), although without statistical sig-
nificance. Use of a lower INR range may also result in a
nonsignificant increase in the risk of mortality (RR, 2.00; 95%
CI, 0.86-4.47; ARR, 22 more per 1000 patients; 95% CI, 3
fewer to 75 more; moderate-certainty evidence) and major
bleeding (RR, 1.13; 95% CI, 0.44-2.88; ARR, 3 more per 1000
patients; 95% CI, 12 fewer to 41 more; moderate-certainty
evidence).
Certainty in the evidence of effects
The certainty in the evidence was judged moderate for mortality,
major bleeding, PE, and DVT due to imprecision, given the small
number of events in both arms not meeting optimal information size
and the fact that the CI around the absolute estimates likely crossed
the thresholds that patients would consider important. Therefore, it
was not possible to completely rule out a small difference between
the alternatives on such outcomes.
Other EtD criteria and considerations
We considered that avoidance of PE, DVT, and major bleeding
was critical for patients. Patients placed a high value on the
benefits of risk reduction in VTE recurrence and PTS.311
However, the panel considered the existence of an important
variability in how individual patients may value the risk of recurrent
VTE vs the risk of bleeding. The panel considered a negligible cost
and savings between the interventions. One Markov model272
compared an unlimited duration of conventional-intensity anti-
coagulation (INR range, 2.0-3.0) vs low-intensity anticoagulation
(INR range, 1.5-2.0) with warfarin. The analysis suggested that
an unlimited duration of standard-intensity anticoagulation was
always more cost-effective.
The panel thought that there was no impact on health equity when
choosing either intervention. The panel considered that a low target
INR with warfarin was probably feasible but not acceptable to key
stakeholders.
Conclusions and implementation considerations
This recommendation specifically applies to patients who are going
to be treated with VKAs for secondary prevention of VTE. The ASH
guideline panel provided a strong recommendation for VKAs with
an INR range of 2.0 to 3.0 over an INR range of 1.5 to 1.9. However,
it should be noted that patients considered to have a “high risk of
bleeding” were excluded from the randomized trial described in the
analysis above.316 Decisions concerning anticoagulant therapy with
warfarin for patients with a significant bleeding risk need to be
individualized, and a VKA may not be the optimal anticoagulant in
this setting.
Recommendation 22
For patients with DVT and/or PE who have completed primary
treatment and will continue with a DOAC for secondary pre-
vention, the ASH guideline panel suggests using standard-
dose DOAC or lower-dose DOAC (conditional recommenda-
tion based on moderate certainty in the evidence of effects
ÅÅÅ○).
Remarks: Lower-dose DOAC regimens that may be consid-
ered for patients who have completed primary treatment and
will continue with a DOAC include rivaroxaban at 10 mg daily
and apixaban at 2.5 mg twice daily.
Summary of the evidence
We identified 2 RCTs306,314 to inform this recommendation. Trials
included adults with objectively confirmed DVT and/or PE who had
been treated with anticoagulants for 6 to 12 months. Subsequently,
patients were randomized to receive 20 mg or 10 mg of
rivaroxaban daily in 1 trial314 or 5 mg or 2.5 mg of apixaban twice
daily in another trial306 for 12 months. The follow-up time ranged




The analysis showed that, compared with a standard dose of
rivaroxaban or apixaban, treating patients with a lower DOAC dose
was associated with a nonsignificant reduction in the risk of
mortality (RR, 0.68; 95% CI, 0.10-4.57; ARR, 2 fewer per 1000
patients; 95% CI, 6 fewer to 22 more; low-certainty evidence). The
lower DOAC dose had little impact on the risk of DVT (RR, 0.75;
95% CI, 0.36-1.53; ARR, 2 fewer per 1000 patients; 95% CI, 6
fewer to 5 more; moderate-certainty evidence) or the risk of major
bleeding (RR, 0.97; 95% CI, 0.12-1.95; ARR, 0 fewer per 1000
patients; 95% CI, 2 fewer to 7 more; moderate-certainty evidence).
Harms and burden
The use of a lower-dose DOAC compared with a standard-dose
DOAC was associated with a nonsignificant increase in the risk of
nonfatal PE (RR, 1.25; 95% CI, 0.54-2.91; ARR, 1 more per 1000
patients; 95% CI, 2 fewer to 10 more; moderate-certainty
evidence).
Certainty in the evidence of effects
The certainty in the evidence was judged moderate for major bleeding,
nonfatal PE, and DVT because of imprecision, given the small number
of events in both arms not meeting optimal information size and the fact
that the CI around the absolute estimates likely crossed the thresholds
that patients would consider important. Therefore, it was not possible
to completely rule out a small difference between the alternatives on
such outcomes. The certainty in the evidence was judged low
for mortality because of the reasons mentioned above, as well as
the large unexplained heterogeneity.
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Other EtD criteria and considerations
The panel considered that there was important variability in how
individual patients might value the risk of thrombosis vs the risk of
bleeding. The panel estimated that the cost of a DOAC does not
vary significantly with the dose.
The panel considered that both interventions were probably
acceptable to relevant stakeholders and feasible to implement.
Conclusions and implementation considerations
Three DOACs have been studied for secondary prevention of
recurrent VTE after completion of the primary treatment
phase.306,310,314 Two of these agents, rivaroxaban and apixaban,
have been studied at a reduced dose: from 20 mg daily to 10 mg
daily for rivaroxaban and 5 mg to 2.5 mg twice daily for
apixaban.306,314 The investigation into the use of the lower
doses of these 2 anticoagulants for secondary prevention was
prompted by the desire to reduce the risk of bleeding, as well as
the documented efficacy of the lower doses to prevent VTE after
elective hip or knee arthroplasty.317-321 However, neither study
was powered for the comparisons between the standard and low
doses. In addition, patients with a higher risk of recurrence were
excluded from the studies (eg, multiple prior unprovoked VTE,
indication for therapeutic dose anticoagulation, or antiphospho-
lipid syndrome). Given the moderate certainty in the evidence of
effects, the ASH guideline panel has provided a conditional
recommendation that the standard dose or the lower dose of
rivaroxaban or apixaban may be used for the secondary prevention
of VTE. For patients who are treated with dabigatran for secondary
prevention, only the standard regimen of 150 mg twice daily has
been studied.310
Additional research is necessary to identify which subsets of
patients who are going to continue anticoagulant therapy
indefinitely for secondary prevention can safely use a lower-
dose DOAC and which patients should be maintained on
a standard dose (eg, obese individuals and patients at higher
risk for recurrence).
Treatment of recurrent events
Recommendation 23
For patients with breakthrough DVT and/or PE during thera-
peutic VKA treatment, the ASH guideline panel suggests using
LMWH over DOAC therapy (conditional recommendation
based on very low certainty in the evidence of effects Å○○○).
Remarks: Patients who present with a new VTE during ther-
apeutic treatment with a VKA should be further investigated to
identify potential underlying causes. This recommendation
does not include patients who develop breakthrough VTE in
the setting of poor INR control, in whom a DOAC may be
a reasonable option.
Summary of the evidence
We did not find any systematic review or randomized trial
comparing DOACs vs LMWH for patients with recurrent DVT
and/or PE during treatment with VKA. DOACs vs LMWH have
been compared only in the setting of VTE prophylaxis, which we
considered too indirect to make judgments about VTE treat-
ment. The online EtD framework is available here: https://
guidelines.gradepro.org/profile/4D133D47-A600-EC68-85E9-
5221E45B47F9.
Benefits, harms, and burden
Given the lack of evidence, we were unable to estimate the benefits
and harms.
Certainty in the evidence of effects
The certainty in the evidence was judged very low for all of the
relevant outcomes.
Other EtD criteria and considerations
We did not find any economic evaluation assessing the cost utility of
a DOAC vs LMWH for patients with DVT and/or PE during
treatment with VKA. Both interventions are widely available, and
factors such as the route of administration (subcutaneous vs oral),
cost, and coverage by health insurance will probably influence
patients’ preferences.
Conclusions and implementation considerations
The risk of recurrent VTE while on anticoagulant therapy with
a VKA was 1.6% in a Cochrane meta-analysis.245 Frequent
reasons associated with breakthrough thromboembolic events
include the underlying condition or disease (eg, cancer,
antiphospholipid syndrome, or vasculitis) or inappropriate
selection and/or dosing of the anticoagulant (eg, noncompli-
ance, drug-drug interactions, and drug-food interactions).322 An
initial assessment of any patient with an apparent breakthrough
VTE while on therapeutic anticoagulation includes confirmation
of compliance with the therapy being administered and
confirmation that the medication and dosing regimen are
appropriate for the individual patient. Initial laboratory testing
includes an INR to confirm the patient is therapeutically
anticoagulated with a VKA.
A recurrent or breakthrough event for patients receiving a VKA who
were recently being treated with UFH or, less commonly, a LMWH
may be suggestive of heparin-induced thrombocytopenia (HIT). In
this setting, the VKA should be discontinued, the anticoagulant
effect should be reversed with vitamin K, and the patient should be
started on a nonheparin anticoagulant. The diagnosis and treatment
of patients with suspected HIT are discussed in a separate ASH
guideline document.323
For patients who sustain a breakthrough thrombotic event while
taking a VKA who do not have HIT, there are minimal data available
concerning which anticoagulant to select. The ASH guideline panel
has provided a conditional recommendation favoring anticoagula-
tion with LMWH over a DOAC, but this recommendation is based
on very low certainty in the evidence of effects. These patients need
to be carefully evaluated for underlying conditions and potential
contraindications to individual anticoagulant agents, such as
antiphospholipid syndrome, in which LMWH may be preferred over
a DOAC. In addition, these patients need to be reevaluated when
clinically stable to determine whether they need to continue LMWH
or switch to an oral agent.
The evaluation and management of patients who sustain recurrent
thromboembolic events while taking therapeutic anticoagulation
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constitute an area needing well-designed prospective studies to
provide guidance.
Recommendation 24a
For patients who develop DVT and/or PE provoked by a tran-
sient risk factor and have a history of previous unprovoked VTE
or VTE provoked by a chronic risk factor, the ASH guideline
panel suggests continuing antithrombotic therapy over stop-
ping anticoagulation after completing primary treatment (con-
ditional recommendation based on moderate certainty in the
evidence of effects ÅÅÅ○).
Recommendation 24b
For patients who develop a DVT and/or PE provoked by
a transient risk factor and have a history of a previous throm-
botic event also provoked by a transient risk factor, the ASH
guideline panel suggests stopping anticoagulation after com-
pletion of the primary treatment phase of therapy over indefinite
duration therapy (conditional recommendation based on
moderate certainty in the evidence of effects ÅÅÅ○).
Remarks: For guidance on selection of antithrombotic therapy
after completion of primary treatment, see Recommendation 20.
Summary of the evidence
We identified 19 systematic reviews239-257 and 13
RCTs88,258,259,261,262,265,267,298,306-310 (n 5 8593) to inform
this recommendation. Trials included adults with objectively con-
firmed DVT and/or PE who had been treated with anticoagulants for
$3 months without recurrence, referred to as the “study population”
below. Patients were subsequently randomized to placebo or extended
anticoagulation for $6 months of additional treatment. The mean
follow-up time varied from 24 to 28 months for different outcomes. The
outcomes were measured in both groups immediately at the end of the
extended-duration treatment. For baseline risks of VTE, we used
a prospective cohort study324 that reported an incidence rate for
recurrent VTE of 5.6 per 100 patient-years for patients with a provoked
VTE who had discontinued anticoagulation after completion of primary
treatment. For patients with recurrent provoked VTE, assuming that
45% of the VTE events are PEs and 55% are DVTs,269 we estimated
the risks of PE recurrence to be 2.5 per 100 patient-years and the risks
of DVT recurrence to be 3.1 per 100 patient-years. These estimates,
however, do not differentiate the risk of recurrence according to the
nature of the first thrombotic episode (ie, provoked or unprovoked). For
the baseline risk of major bleeding, we used data from 2 randomized
trials on people with VTE; the risk of major bleeding with placebo
during an 18- or 24-month treatment with anticoagulants was as low as
0.5%306 and as high as 1.5% in 18 months.259 The EtD framework is
shown online at: https://guidelines.gradepro.org/profile/D9F5564D-
D7EE-97A3-8AAB-24FF9D0C32F4.
Benefits
The meta-analysis showed that, compared with discontinuation
of anticoagulation, treating patients with indefinite antithrom-
botic therapy reduced the risk of PE in the study population (RR,
0.29; 95% CI, 0.15-0.56; ARR, 21 fewer per 1000 patients;
95% CI, 25 fewer to 13 fewer; high-certainty evidence), as
well as for patients with recurrent provoked VTE269,324 (ARR,
18 fewer per 1000 patients; 95% CI, 21 fewer to 11 fewer;
high-certainty evidence). Indefinite antithrombotic therapy also
showed a risk reduction in DVT (RR, 0.20; 95% CI, 0.12-0.34;
ARR, 50 fewer per 1000 patients; 95% CI, 56 fewer to 42 fewer;
high-certainty evidence). Indefinite antithrombotic therapy also
reduced the risk of DVT for patients with recurrent provoked
VTE at 1 year269,324 (ARR, 25 fewer per 1000 patients; 95% CI,
27 fewer to 20 fewer).
There were significant subgroup effects with the different
antithrombotic interventions on DVT outcome.When using a DOAC
for indefinite anticoagulation, the risk of DVT was reduced in the
study population (RR, 0.15; 95% CI, 0.10-0.23; ARR, 49 fewer per
1000 patients; 95% CI 51 fewer to 44 fewer; high-certainty
evidence), as well as for patients with recurrent provoked
VTE269,324 (ARR, 26 fewer per 1000 patients; 95% CI, 28 fewer
to 24 fewer; high-certainty evidence). When using a VKA or LMWH
for indefinite anticoagulation, we observed a reduction in the risk of
recurrent DVT in the study population (RR, 0.17; 95% CI, 0.05-
0.53; ARR, 54 fewer per 1000 patients; 95% CI, 61 fewer to 30
fewer), as well as for patients with recurrent provoked VTE (ARR, 26
fewer per 1000 patients; 95% CI, 29 fewer to 14 fewer; high-
certainty evidence).269,324 Aspirin reduced the risk of DVT in the
study population (RR, 0.55; 95% CI, 0.31-0.98; ARR, 64 fewer per
1000 patients; 95% CI, 98 fewer to 3 fewer), as well as for patients
with recurrent provoked VTE (ARR, 14 fewer per 1000 patients;
95% CI, 21 fewer to 1 fewer; moderate-certainty evidence).269;324
Our analysis showed a potential decrease in mortality when using
indefinite antithrombotic therapy compared with a defined duration
of anticoagulation, without statistical significance (RR, 0.75; 95%
CI, 0.49-1.13; ARR, 5 fewer per 1000 patients; 95% CI, 9 fewer to
2 more; moderate-certainty evidence).
Harms and burden
The use of indefinite antithrombotic therapy increased the risk of
major bleeding (RR, 2.17; 95%CI, 1.40-3.35; ARR, 6 more per 1000
patients; 95% CI, 2 more to 12 more; high-certainty evidence). In
populations with a high risk for bleeding,259 the use of indefinite
antithrombotic therapy instead of a defined duration of anticoagula-
tion led to an increase of 18 more major bleeding events per 1000
patients (95% CI, 6 more to 35 more; high-certainty evidence).
Certainty in the evidence of effects
The certainty in the evidence was judged high for PE, DVT, and
major bleeding but moderate for mortality because of imprecision,
given that the CI around the absolute estimates crossed thresholds
that patients would likely consider important. Therefore, it was not
possible to completely rule out a small difference between the
alternatives on mortality. In the subgroup analysis performed for
DVT, when using aspirin, the certainty in the evidence was judged
moderate because of imprecision.
Other EtD criteria and considerations
We considered that avoidance of PE, DVT, and major bleeding was
critical for patients. Patients placed a high value on the benefits of
risk reduction in VTE recurrence and PTS.311 However, there is
important variability in how individual patients may value the risk of
thrombosis vs the risk of bleeding.
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We did not identify a cost-effectiveness comparison for nonsurgical
provoked VTE. Four Markov model analyses of cost-effectiveness for
extended antithrombotic therapy vs limited antithrombotic therapy
for VTE treatment were identified. Three analyses showed that the
extended strategy was cost-effective compared with limited
antithrombotic therapy,112,270,271 whereas 1 analysis suggested
that longer initial conventional-intensity anticoagulation with
warfarin was cost-effective in younger patients, and 3 months of
anticoagulation was preferred in elderly patients ($80 years
old).272 The panel considered that cost-effectiveness varies with
patients, the chronic risk factor(s) contributing to risk of recurrent
VTE, and the antithrombotic therapy used.
The panel considered that indefinite treatment was probably
feasible but that acceptability varied.
Conclusions and implementation considerations
This recommendation applies to the patient who sustains a VTE
related to a transient risk factor, who also has a history of VTE that
was unprovoked or provoked by a chronic risk factor (Recommen-
dation 24a) or who has a history of VTE that was provoked by
a transient risk factor (Recommendation 24b). These patients need
to undergo decisions about initial management (Recommendations
1 to 11) and primary treatment (Recommendations 12 to 14), just
as with their first event. If the first event carried a high risk for
recurrence (eg, was unprovoked), the ASH guideline panel
provided a conditional recommendation in support of indefinite
antithrombotic therapy for secondary prevention after completion of
the primary treatment phase. In contrast, if the first event carried
a lower risk for recurrence (ie, was provoked by a transient risk
factor), the panel provided a conditional recommendation favoring
discontinuation of anticoagulation after completion of the primary
treatment phase. Variables that may impact on decision making
for the individual patient, particularly the patient with a first event
considered high risk for recurrence, might include whether
the second event occurred in the same vascular distribution as
the first event, the presence (or absence) of an underlying
hypercoagulable state, the development of hemorrhagic com-
plications while on anticoagulant therapy, and/or the clinical
severity of the second event (eg, massive PE vs popliteal DVT).
For those patients continued on indefinite antithrombotic therapy
for secondary prevention, decisions about the optimal antithrom-
botic strategy for secondary prevention are addressed in Recom-
mendations 20 to 22.
Recommendation 25
For patients with a recurrent unprovoked DVT or PE, the ASH
guideline panel recommends indefinite antithrombotic therapy
over stopping anticoagulation after completion of primary
treatment (strong recommendation based on moderate cer-
tainty in the evidence of effects ÅÅÅ○).
Remarks: For guidance on selection of antithrombotic therapy
after completion of primary treatment, see Recommendation 20.
Summary of the evidence
We identified 19 systematic reviews239-257 and 13
RCTs88,258,259,261,262,265,267,298,306-310 (n 5 8593) to inform this
recommendation. Trials included adults with objectively confirmed
DVT and/or PE who had been treated with anticoagulants for
$3 months without recurrence, referred to as the “study
population” below. Patients were subsequently randomized to
receive placebo or continue antithrombotic therapy for $6
additional months. The mean follow-up varied from 24 to 28 months
for different outcomes. The outcomes were measured in both
groups immediately at the end of the longer course of anti-
coagulation. For baseline risks of VTE, we used a prospective
cohort study324 that reported a risk for patients with a recurrent
unprovoked VTE of 12 per 100 patient-years. Assuming that 45% of
the VTE events are PEs and 55% are DVTs,269 we estimated the
risks of PE recurrence to be 5.4 per 100 patient-years and the risks
of DVT recurrence to be 6.6 per 100 patient-years for patients with
recurrent unprovoked VTE. For the baseline risk of major bleeding,
we used data from 2 randomized trials on people with VTE; the risk
of major bleeding with placebo during an 18-month or 24-month
treatment with anticoagulants was as low as 0.5%306 and as high




The meta-analysis showed that, compared with discontinuation of
anticoagulation, treating patients with indefinite antithrombotic
therapy reduced the risk of PE in the study population (RR, 0.29;
95% CI, 0.15-0.56; ARR, 21 fewer per 1000 patients; 95% CI, 25
fewer to 13 fewer; high-certainty evidence), as well as for patients
with recurrent unprovoked VTE269,324 (ARR, 38 fewer per 1000
patients; 95% CI, 46 fewer to 24 fewer; high-certainty evidence).
Indefinite antithrombotic therapy also showed a risk reduction in
DVT (RR, 0.20; 95% CI, 0.12-0.34; ARR, 50 fewer per 1000
patients; 95% CI, 56 fewer to 42 fewer; high-certainty evidence).
For patients with recurrent unprovoked VTE at 1 year,269,324
indefinite antithrombotic therapy also reduced the risk of DVT
(ARR, 53 fewer per 1000 patients; 95% CI, 58 fewer to 44
fewer).
There were significant subgroup effects associated with the
different antithrombotic interventions on DVT outcome. When
using a DOAC for indefinite anticoagulation, the risk of DVT was
reduced in the study population (RR, 0.15; 95% CI, 0.10-0.23;
ARR, 49 fewer per 1000 patients; 95% CI, 51 fewer to 44 fewer;
high-certainty evidence) as well as for patients with recurrent
unprovoked VTE269,324 (ARR, 56 fewer per 1000 patients; 95% CI,
59 fewer to 51 fewer; high-certainty evidence). When a VKA or
LMWH was used for indefinite anticoagulation, we observed a re-
duction in the risk of DVT in the study population (RR, 0.17; 95% CI,
0.05-0.53; ARR, 54 fewer per 1000 patients; 95% CI, 61 fewer to 30
fewer), as well as for patients with recurrent unprovoked VTE (ARR, 55
fewer per 1000 patients; 95%CI, 63 fewer to 31 fewer; high-certainty
evidence).269,324 Aspirin also reduced the risk of recurrent DVT in the
study population (RR, 0.55; 95% CI, 0.31-0.98; ARR, 64 fewer per
1000 patients; 95% CI, 98 fewer to 3 fewer), as well as for patients
with recurrent unprovoked VTE (ARR, 30 fewer per 1000 patients;
95%CI, 46 fewer to 1 fewer; moderate-certainty evidence).269,324 Our
analysis showed a potential decrease in mortality when using indefinite
antithrombotic therapy compared with a defined duration of anti-
coagulation, without statistical significance (RR, 0.75; 95% CI, 0.49-
1.13; ARR, 5 fewer per 1000 patients; 95% CI, 9 fewer to 2 more;
moderate-certainty evidence).
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Harms and burden
The use of indefinite antithrombotic therapy increased the risk of
major bleeding (RR, 2.17; 95% CI, 1.40-3.35; ARR, 6 more per
1000 patients; 95% CI, 2 more to 12 more; high-certainty
evidence). In populations with a high risk for bleeding,259 the use
of indefinite antithrombotic therapy instead of a defined duration of
anticoagulation led to an increase of 18 more major bleeding events
per 1000 patients (95% CI, 6 more to 35 more; high-certainty
evidence).
Certainty in the evidence of effects
The certainty in the evidence was judged high for PE, DVT, and
major bleeding but moderate for mortality because of impreci-
sion given that the CI around the absolute estimates crossed
thresholds that patients would likely consider important.
Therefore, it was not possible to completely rule out a small
difference between the alternatives on mortality. In the sub-
group analysis performed for DVT, when using aspirin the
certainty in the evidence was judged moderate because of
imprecision.
Other EtD criteria and considerations
We considered that avoidance of PE, DVT, and major bleeding was
critical for patients. Patients placed a high value on the benefits of
risk reduction in VTE recurrence and PTS.310 However, there is
important variability in how individual patients may value the risk of
thrombosis vs the risk of bleeding.
We did not identify direct evidence on a cost-effectiveness
comparison for nonsurgical provoked VTE. Four Markov model
analyses of cost-effectiveness for extended antithrombotic therapy
vs limited antithrombotic therapy for VTE treatment were identified.
Three analyses showed that the extended strategy was cost-effective
compared with the limited antithrombotic therapy,112,270,271
whereas 1 analysis suggested that longer initial conventional-
intensity anticoagulation with warfarin was cost-effective in
younger patients, and 3 months of anticoagulation was preferred
in elderly patients ($80 years old).272 The panel considered that
cost-effectiveness varies with patients, the chronic risk factor(s)
contributing to risk for recurrent VTE, and drug used.
The panel considered that indefinite treatment was probably
feasible but that acceptability varies.
Conclusions and implementation considerations
This recommendation applies to the patient who sustains an
unprovoked VTE and who also has a history of an unprovoked VTE
that was treated with a time-limited course of therapy that had been
discontinued prior to the current event. These patients need to
undergo decisions about initial management (Recommendations 1
to 11) and primary treatment (Recommendations 12 to 14), just as
with their initial event. The ASH guideline panel provided a strong
recommendation in favor of indefinite antithrombotic therapy for
secondary prevention of recurrent thromboembolism in light of the
very high risk of recurrence off anticoagulation. Decisions about the
optimal antithrombotic strategy for secondary prevention would be




For patients with DVT and/or PE with stable CVD who initiate
anticoagulation and were previously taking aspirin for cardio-
vascular risk modification, the ASH guideline panel suggests
suspending aspirin over continuing it for the duration of anti-
coagulation therapy (conditional recommendation based on
very low certainty in the evidence of effects Å○○○).
Remarks: A critical review of the indication for aspirin therapy is
needed at the time anticoagulant therapy is initiated, consid-
ering the increased risk of bleeding vs the potential benefit in
terms of cardiovascular prevention. This recommendation does
not apply to patients with a recent acute coronary event or
coronary intervention.
Summary of the evidence
We identified 13 RCTs (n 5 7928) to inform this recommen-
dation.325-337 Trials included PE patients who were previ-
ously receiving aspirin for prevention of CVD and had initiated
anticoagulation therapy. Patients who received an initial course
of anticoagulants were randomized to anticoagulant with aspirin
or anticoagulants alone. The mean follow-up time varied from




An assessment of the benefits of aspirin was not relevant to
a guideline of VTE treatment and, therefore, was considered outside
the scope of this analysis.
Harms and burden
Evidence from included RCTs suggested that treating PE patients
who had previously received aspirin for the prevention of CVD with
anticoagulation with aspirin increased the risk of major bleeding
compared with anticoagulation alone (RR, 1.26; 95% CI, 0.92-
1.72; ARR, 7 more per 1000 patients; 95% CI, 2 fewer to 21 more;
very-low-certainty evidence). In patient populations with any in-
dication for anticoagulation and/or aspirin,98 the use of anti-
coagulation with aspirin relative to anticoagulation alone led to an
increase of 5 more major bleeding events per 1000 patients (95%
CI, 2 fewer to 15 more; very-low-certainty evidence).
Certainty in the evidence of effects
The certainty in the evidence from the included RCTs was judged
very low for major bleeding because of a serious risk for bias,
indirectness, and imprecision. First, there was a lack of allocation
concealment and blinding of study participants and personnel
across the different studies. Second, the pooled CIs included the
null, as well as appreciable benefit and harm. Third, the included
trials were conducted for patients without VTE.
Other EtD criteria and considerations
The panel considered that aspirin discontinuation was probably
feasible but that acceptability varies.
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Conclusions and implementation considerations
Patients may be taking aspirin daily for prevention of CVD at the
time of diagnosis with a VTE. For patients taking aspirin for primary
prevention of CVD or for stable coronary artery disease, the ASH
guideline panel provides a conditional recommendation in favor of
suspending aspirin while taking anticoagulant therapy, based on
a very low level of certainty in the evidence. For secondary
prevention for patients with stable coronary artery disease, studies
have found oral anticoagulants to be effective, with a decreased risk
for bleeding compared with the combination of an anticoagulant
and aspirin.330-38 This recommendation does not apply to patients
with a recent acute coronary event or coronary intervention. A similar
approach has been advocated for patients who are taking anticoag-
ulant therapy for atrial fibrillation who have concomitant CVD.339
Research needs relevant to this recommendation include studies to
determine which patients should continue antiplatelet therapy when
anticoagulant therapy is initiated for the treatment of VTE. In addition,
research is needed to determine which anticoagulant agent(s) and
dose(s) are safest when coadministered with antiplatelet therapy.
Recommendations 27 and 28
For patients with DVT, with (Recommendation 27) or without
(Recommendation 28) increased risk for PTS, the ASH
guideline panel suggests against the routine use of compres-
sion stockings (conditional recommendation based on very low
certainty in the evidence of effects Å○○○).
Remarks: Although the majority of patients may not benefit
from the use of stockings to reduce the risk of PTS, stockings
may help to reduce edema and pain associated with DVT in
selected patients.
Summary of the evidence
We identified 10 systematic reviews340-349 and 6 relevant
randomized trials260,350-354 (n 5 1393). All of the identified trials,
with the exception of the SOX trial, compared the use of stockings
vs no stockings for patients with proximal DVT. Typically, the
intervention group received an elastic stocking on the affected leg
with an ankle pressure of 30 to 40 mm Hg for 6 to 24 months.
Participants were followed for a period of 2 to 5 years and were
periodically assessed for the development of PTS. The definition of
PTS was variable in the different trials, although the Villalta scale355
was used most frequently. The sample size in the SOX trial353
(n 5 806) was larger than in the rest of the trials, and patients
with proximal DVT were randomized to elastic stockings with an
ankle pressure of 30 to 40 mm Hg or to placebo stockings with
an ankle pressure #5 mm Hg for 2 years. The investigators
reported the incidence of PTS at the end of follow-up using
different definitions, including the Villalta criteria. The EtD
framework is shown online at: https://guidelines.gradepro.org/
profile/88899593-89FA-D803-95A0-B9E113F2B50D (Recommen-
dation 27) and https://guidelines.gradepro.org/profile/77202CC8-
4CE2-DE7B-8EFF-96F7C0E80DFD (Recommendation 28).
Benefits
The use of compression stockings has a negligible effect on
mortality (RR, 0.99; 95% CI, 0.72-1.36; ARR, 0 fewer per 1000
patients; 95% CI, 13 fewer to 17 more; moderate-certainty
evidence). We did observe a nonsignificant reduction in the risk
of PE (RR, 0.72; 95% CI, 0.31-1.70; ARR, 4 fewer per 1000
patients; 95% CI, 10 fewer to 10 more; low-certainty evidence);
however, this outcome was reported in only 1 trial, and the number
of events was very small.
Pooling all identified trials, we observed a nonsignificant reduction
in the risk of PTS (RR, 0.62; 95% CI, 0.38-1.01; ARR, 81 fewer per
1000 patients; 95% CI, 132 fewer to 2 more; very-low certainty
evidence). However, when we considered only the trials with a low
risk for bias, this potential benefit was not observed (RR, 1.01; 95%
CI, 0.76-1.33). The same occurred with the risk of DVT. Pooling all
trials, we observed a nonsignificant reduction in DVT (RR, 0.56;
95% CI, 0.12-2.70; ARR, 18 fewer per 1000 patients; 95% CI, 35
fewer to 68 more; low-certainty evidence), although this did not hold
in the subgroup of trials with a low risk for bias (RR, 1.08; 95% CI,
0.69-1.71).
Harms and burden
We did not identify harmful effects of stockings. However, some
patients may experience discomfort, skin breakdown, allergic
reaction, or significant cost to acquire the stockings.
Certainty in the evidence of effects
The main limitations of the evidence identified were the risk of bias
and the small number of patients studied (imprecision). The effect of
compression stockings on PTS and DVT observed in the SOX trial
was significantly different from the results of unblinded trials, as
demonstrated by the tests for interaction.
Additionally, for all of the outcomes, the number of patients studied
and number of events were relatively small, and the CI around the
absolute estimates likely crossed the thresholds that patients would
consider important.
Other EtD criteria and considerations
There is probably important variability in patients’ preferences:
although some may experience relief of pain and edema,
compression of the leg may be associated with discomfort in others.
We did not find any economic evaluation assessing the cost utility of
compression stockings, although we considered that maintaining
stockings for a long period of time implied a moderate cost.
Finally, stockings are generally available, although they may not be
acceptable for some patients and providers given the uncertainty
regarding their effect.
Conclusions and implementation considerations
PTS may develop in up to 30% to 50% of patients following the
development of proximal DVT,149,150 and it may be severe in 5% to
10% of patients.3,150 Some patients may experience symptomatic
benefit from wearing compression stockings but, as noted above,
there was inconsistent evidence that compression stockings can
decrease the risk of developing PTS. Consequently, given the very
low level of certainty in the evidence, the ASH guideline panel
suggests against the routine use of compression stockings for
patients with DVT, with or without an increased risk for PTS.
Research priorities should focus on the identification of the subsets
of patients who would potentially benefit from the use of compression
stockings.
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What are others saying, and what is new?
There are 4 recent guideline documents concerning the manage-
ment of patients with VTE. The 2016 guideline and expert panel
report on antithrombotic therapy for VTE from the American College
of Chest Physicians (ACCP)356 is an update of the 2012 ACCP
guidelines.312 A second guidance document on the treatment of
VTE, endorsed by the Anticoagulation Forum (ACF) Board of
Directors, was also published in 2016.357 The European Society of
Cardiology has published separate consensus documents on the
diagnosis and management of DVT358 and PE.238 Differences
between the ASH guidelines and these documents include the
consistent use of systematic reviews and EtD frameworks, which
increase transparency, and the use of marker states to estimate the
relative importance to patients of key outcomes of treatment.
As with prior guidelines, the ASH guideline panel has given consider-
able thought to distinguishing the primary treatment phase of VTE (first
3-6 months) from the secondary prevention phase (indefinite duration
following the primary treatment phase; Figure 2). Important decisions
concerning which patients should receive indefinite preventive therapy
following completion of the primary treatment phase, as well as what
antithrombotic therapy should be administered, must have these
unique phases of treatment clearly defined. Prior terminology has been
confusing, with the primary treatment phase described as “long term”
in the 2016 ACCP guidelines and “short term” in the 2016 ACF
guidance document; the secondary prevention phase is referred to as
“extended” in the 2016 ACCP guidelines and “long term” in the 2016
ACF guidance document. Our choice of terminology reflects the
distinct clinical intention of the 2 phases of VTE management, rather
than terms reflecting the relative duration of therapy.
New questions addressed in the ASH guidelines include recom-
mendations concerning whether 1 DOAC should be preferred over
another for the primary treatment phase (Recommendation 4),
whether prognostic scores, D-dimer testing, and/or ultrasound
testing should be routinely used to guide decision making
concerning continuing therapy after completion of the primary
phase of treatment (Recommendations 15 to 17), whether patients
receiving rivaroxaban or apixaban for secondary prevention therapy
should receive standard-dose or lower-dose therapy (Recommen-
dation 22), and whether patients who have previously sustained
a VTE and completed a course of primary treatment, who now
sustain a recurrent event associated with a transient risk factor,
should receive secondary prevention after completion of the primary
treatment phase of therapy (Recommendations 24a and 24b). The
ASH guidelines also address the question of whether aspirin should
be continued or discontinued during anticoagulation in those patients
who sustain a VTE while taking aspirin (Recommendation 26).
The ASH guidelines incorporate the most recent systematic
reviews, RCTs, and observational studies, as well as information
concerning cost of interventions and health equity, in the final
recommendations that have been generated. When appropriate,
the panel has also provided suggestions for areas in which future
research is needed to address questions important to patients with
VTE and their providers.
Limitations of these guidelines
Treatment of VTE in day-to-day practice poses many challenges to
clinicians. We acknowledge that not all of them are covered in this
guideline. However, the guideline model implemented by ASH can
be easily updated in the future, adding new recommendations to
those already published.
Panelists recommended or suggested courses of action based on the
evidence available at the moment of development of this guideline.
However, new evidence may change the recommendations in the
future, especially those based on low- or very-low-certainty evidence.
Finally, the recommendations are meant to inform the decisions of
clinicians and patients. They do not, however, replace the careful
consideration of the specific clinical circumstances and patients’
values and preferences.
Plans for updating these guidelines
After publication of these guidelines, ASH will maintain them
through surveillance for new evidence, ongoing review by experts,
and regular revisions.
Adapting recommendations locally
Although ASH guidelines have a global scope, the recommenda-
tions in this article were developed primarily for North America.
Likely, resource considerations, feasibility, and acceptability of
interventions may vary in different regions.
The “Adolopment” model of guideline adoption, adaptation, and
development359 offers an approach to adapt the recommendations
of this article to a specific context, taking advantage of the EtD
frameworks accompanying each recommendation. Local guideline
groups may reuse the evidence collected and appraised on the
frameworks. By adding relevant local information, they can generate
local recommendations with fewer resources than those required
to develop a guideline de novo.
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2. Jiménez D, Aujesky D, Moores L, et al; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with
acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383-1389.
3. Baldwin MJ, Moore HM, Rudarakanchana N, Gohel M, Davies AH. Post-thrombotic syndrome: a clinical review. J Thromb Haemost. 2013;11(5):
795-805.
4. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-474.
5. Delluc A, Le Mao R, Tromeur C, et al. Incidence of upper-extremity deep vein thrombosis in western France: a community-based study. Haematologica.
2019;104(1):e29-e31.
6. Grant JD, Stevens SM, Woller SC, et al. Diagnosis and management of upper extremity deep-vein thrombosis in adults. Thromb Haemost. 2012;108(6):
1097-1108.
7. Cushman M, Tsai AW,White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism
etiology. Am J Med. 2004;117(1):19-25.
8. HuangW, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: theWorcester VTE study
(1985-2009). Am J Med. 2014;127(9):829-839.e5.
9. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study
Cohort. Am J Med. 2013;126(9):832.e13-832.e21.
10. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors:
prospective cohort study. Lancet. 2003;362(9383):523-526.
11. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on
risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036.
12. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute
proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205.
13. Rabinovich A, Kahn SR. How I treat the postthrombotic syndrome. Blood. 2018;131(20):2215-2222.
14. Pengo V, Lensing AW, Prins MH, et al; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary
hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-2264.
15. Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133(5):425-435.
16. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism:
a 25-year population-based study. Arch Intern Med. 1998;158(6):585-593.
17. Zakai NA, McClure LA, Judd SE, et al. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation. 2014;
129(14):1502-1509.
18. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California.
Ann Intern Med. 1998;128(9):737-740.
19. Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Cardiol. 2000;85(11):
1334-1337.
20. Alonso-Coello P, Oxman AD, Moberg J, et al; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent
approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089.
21. Alonso-Coello P, Schünemann HJ, Moberg J, et al; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and
transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.
22. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;
64(4):383-394.
23. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of
recommendations. BMJ. 2008;336(7650):924-926.
24. Schünemann HJ, Mustafa R, Brozek J, et al; GRADE Working Group. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in
clinical practice and public health. J Clin Epidemiol. 2016;76:89-98.
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182. Dotter CT, Seaman AJ, Rösch J, Porter JM. Streptokinase and heparin in the treatment of pulmonary embolism: a randomized comparison. Vasc
Endovascular Surg. 1979;13(1):42-52.
183. Fasullo S, Scalzo S, Maringhini G, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle
dysfunction: comparison of thrombolysis with heparin. Am J Med Sci. 2011;341(1):33-39.
184. Goldhaber SZ, HaireWD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function
and pulmonary perfusion. Lancet. 1993;341(8844):507-511.
185. Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. JAMA. 1970;214(12):2163-2172.
186. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest. 1990;97(3):
528-533.
187. Jerjes-Sanchez C, Ramı́rez-Rivera A, de Lourdes Garcı́a M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism:
a randomized controlled trial. J Thromb Thrombolysis. 1995;2(3):227-229.
188. Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at
3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12(4):459-468.
189. Konstantinides SV, Vicaut E, Danays T, et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am
Coll Cardiol. 2017;69(12):1536-1544.
190. Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk
pulmonary embolism. Circulation. 2014;129(4):479-486.
191. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute
pulmonary embolism. Chest. 1990;98(6):1473-1479.
192. Liu LH, Lu SJ, Liu Z. The effect of thrombolysis and anticoagulation therapy in patients with sub-massive pulmonary embolism [in Chinese]. Chongqing
Med J. 2013;42(11):1288-1290.
193. Lu WH, Tang ZZ, Ma Y, Zh Y. The effectiveness and long-term prognosis of thrombolysis plus anticoagulation therapy versus anticoagulation therapy
alone in patients with sub-massive pulmonary embolism [in Chinese]. Clin J Medical Officer. 2008;36(3):340-342.
194. Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized
clinical trial. Respiration. 1989;54(3):162-173.
195. Meyer G, Vicaut E, Danays T, et al; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;
370(15):1402-1411.
196. Ou YQ. Analysis of the therapeutic effect of urokinase plus sequential anticoagulation for the treatment of sub-massive pulmonary embolism [in Chinese].
J Hainan Medical College. 2012;18(7):897-898.
197. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M; “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the
“MOPETT” Trial). Am J Cardiol. 2013;111(2):273-277.

















L user on 27 O
ctober 2020
198. Sun RQ. Efficacy of urokinase combined with low molecular weight heparin and warfarin for the treatment of sub-massive pulmonary embolism
[in Chinese]. Strait Pharmaceutical J. 2012;24(5):130-131.
199. Taherkhani M, Taherkhani A, Hashemi SR, Faghihi Langroodi T, Sadeghi R, Beyranvand M. Thrombolytic-plus-anticoagulant therapy versus
anticoagulant-alone therapy in submassive pulmonary thromboembolism (TVASPE Study): a randomized clinical trial. J. Tehran Heart Center. 2014;9(3):
104-108.
200. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay
embolism. BMJ. 1974;1(5904):343-347.
201. Wei L, Sun FC. Curative effect of thrombolysis and anticoagulant therapy on submassive pulmonary embolism patients. Int J Respir. 2012;32(19):
1471-1473.
202. Zhang XL, Jiang SH, Jiang LN, Shan FL, Li Z, Qin MH. The effectiveness of low-dose rt-PA thrombolysis in 26 elderly patients with acute sub-massive
pulmonary embolism [in Chinese]. Shandong Yiyao. 2012;52(3):69-70.
203. Ahmed MA, Abdelsalam SI, Elmorsy RA. Value of thrombolytic therapy for submassive pulmonary embolism patients. Egypt J Chest Dis Tuberc. 2018;
67(4):413-418.
204. Zhang LY, Gao BA, Jin Z, et al. Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk
pulmonary embolism. Saudi Med J. 2018;39(11):1090-1095.
205. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation. 2006;113(4):577-582.
206. Lin BW, Schreiber DH, Liu G, et al. Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the
Real World Registry. Am J Emerg Med. 2012;30(9):1774-1781.
207. Kabrhel C, Rosovsky R, Channick R, et al. A multidisciplinary pulmonary embolism response team: initial 30-month experience with a novel approach to
delivery of care to patients with submassive and massive pulmonary embolism. Chest. 2016;150(2):384-393.
208. Xenos ES, Davis GA, He Q, Green A, Smyth SS. The implementation of a pulmonary embolism response team in the management of intermediate- or
high-risk pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2019;7(4):493-500.
209. Rosovsky R, Chang Y, Rosenfield K, et al. Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year
analysis [published correction appears in J Thromb Thrombolysis. 2019;47(1):41]. J Thromb Thrombolysis. 2019;47(1):31-40.
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